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Abstract: 
Birt-Hogg-Dubé Syndrome (OMIM: 135150) is the result of heterozygous germline 
mutations within the Folliculin gene on 17p11.2 and presents with a classic clinical triad of 
symptoms: Kidney neoplasia, spontaneous pneumothorax and fibrofolliculomas (benign skin 
growths). BHD displays no correlation between the type of mutation of the Folliculin gene 
and the phenotype; patients with the same mutations can present with disparate 
phenotypes. There is a known age-dependant penetrance present in BHD. Patients with 
BHD syndrome have an increased risk of Renal Cell Carcinoma (RCC) and associations with 
Colorectal cancers have been found. This study aims to investigate the potential of this 
genotype-phenotype variability in two ways. Firstly, it uses Sanger sequencing to test 
patients for germline polymorphisms known to be associated with susceptibility to renal 
tumours or melanomas to detect a correlation between possible "genetic modifiers" and 
risk of skin and renal tumours in BHD syndrome. Secondly investigating the genetic changes 
involved in renal tumourigenesis in BHD syndrome and sporadic kidney cancer. None of the 
high risk candidate genes were associated with increased risk of tumours in BHD patients. 
Sequencing of a BHD sporadic kidney tumour implicated ARHGEF5 in both BHD and sporadic 
renal tumourigenesis. 
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Introduction 
Cancer (formally known as a malignant neoplasm) is a highly variable spectrum of diseases 
with over 200 distinct forms, that can occur across almost any tissue type within the body 
(UK, 2011). Cancer is widely characterised as uncontrolled proliferation of cells via abnormal 
mitosis, this rapid growth can form malignant tumours that compete with regular tissues for 
resources to the detriment of the organism as a whole. To initiate transformation of a 
regular cell into a cancer cell – Carcinogenesis, a mutation must occur that affects cell 
division, differentiation and/or regulation. This event effectively enhances the cell’s ability 
to divide and grow, providing a clonal advantage to all cells that inherit that mutation 
allowing somatic evolution of those cells by natural selection.  As these cells grow and divide 
they out-compete appropriately regulated cells surrounding them, and continue to acquire 
additional secondary mutations that further enhance their ability to grow.  Under normal 
conditions cell division is tightly regulated, tumour-suppressor genes function by preventing 
carcinogenesis, as a class of genes they can inhibit cell division, initiate apoptosis or other 
protective properties of a cell that might promote their survival. For carcinogenesis to 
proceed, a tumour-suppressor gene is typically lost, or a mutation results in a reduced 
expression of the gene. In contrast to the loss of a tumour-suppressor, a proto-oncogene 
can become mutated into an oncogene which enables cells to avoid apoptosis and continue 
to replicate. Activation of a proto-oncogene occurs primarily by three mechanisms. Direct 
damage to the DNA in the gene itself or the surrounding regulatory region, chromosomal 
abnormalities - translocations or duplications can both result in increased expression or  
dysregulation. Lastly differences in mRNA expression and stability have a profound effect on 
gene expression, resulting in increased expression of oncogene proteins (Ross, 1995). A 
“two-hit” hypothesis was proposed by Knudson; tumour-suppressor genes are typically 
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recessive, if one allele is lost the second copy of the allele might be able to compensate 
though with reduced expression.  Therefore a “second hit” is normally required to remove 
the second alleles’ expression and allow carcinogenesis to progress (Knudson, 1971).   
The ability of cancerous cells to invade other tissues and regions of the body is known as 
metastasis, whilst previously characteristic of late-state malignant tissues recent research 
suggests this ability is not unique to cancer (Podsypanina, et al., 2008). Metastasis is an 
invasive process that typically leads to life-threatening complications and secondary or 
"metastatic" tumours affecting different organ systems. 
Transformation of a regular cell into a cancer cell has distinct hallmarks as codified by 
Hanahan & Weinberg. They described six essential processes that effectuate transformation 
into a tumourigenic cell and the eventual malignancies that develop (Hanahan & Weinberg, 
2000). Mitogenic growth signals and factors for that cell must become self-sufficient with 
lesser dependence on external stimulants, driving further cell growth. Cancer cells can 
produce their own growth factors independently to sustain their proliferation or they can 
induce "regular" cells in the surrounding micro-environment to secrete growth factors via 
reciprocative signalling (Cheng, et al., 2008). Additionally the cancer cells must acquire a 
resistance or insensitivity to inhibitory anti-proliferative signals from surrounding cells to 
prevent growth disrupting homeostatic mechanisms within the tissue. Under normal 
circumstances apoptotic mechanisms drive programmed cell death via extracellular and 
intracellular signals to remove defective or deleterious cells via cell-suicide usually in 
response to stress or damaging conditions. The TP53 gene encoding p53 is the renowned 
"guardian of the genome" and a well characterised tumour-suppressor gene that can 
counteract carcinogenic processes and instability. It accomplishes this by inducing 
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apoptosis, activating DNA repair mechanisms, or arresting the cell cycle growth which allows 
for repair mechanisms to act before cell growth is allowed to continue (Bunz, et al., 1998). It 
can also inhibit angiogenesis - a hallmark discussed below (Dameron, et al., 1994). Naturally 
TP53 is lost in most cancers either by deletion, inactivation or upstream/downstream 
signalling in mutant cells and is a significant factor in carcinogenesis (Bourdon, 2007). Cells 
undergo senescence (biological ageing) and cease dividing  after approximately fifty cell 
cycles - this apparent limit to cell division is known as the "Hayflick limit" (Hayflick & 
Moorhead, 1961) whilst they no longer divide they can remain active in a metabolic sense 
thereby contributing to phenotype. Senescent cells have been implicated in certain diseases 
and age-related disorders and can disrupt nearby cells and cellular functions (Baker, et al., 
2011).  Cells can also undergo senescence in response to environmental conditions or DNA 
damage, the shortening of telomeres at the end of a chromatid is also considered DNA 
damage by the cell. Telomere shortening is a natural process that prevents truncation 
during cell division by allowing the telomere itself to shorten at equivalent rates between 
different cell types (Daniali, et al., 2013).  Evidence in mice suggests that when deliberately 
engineered to lack Telomerase (the enzyme responsible for elongation of telomeres) 
premalignant cells likely to develop into specific tumour types undergo senescence and 
subsequently apoptosis (Artandi & DePinho, 2010). For a proto-cancer cell to continue to 
mutate it must evade these apoptotic and senescent signals and processes. Telomerase is 
typically upregulated in malignant cells, maintaining and extending the telomeres - 
effectively gaining biological immortality and limitless replicative potential. Left unchecked 
these cells will divide continuously until they are limited by the availability of oxygen and 
nutrients constraining the size of the tumour; for the transformation to continue cells must 
acquire angiogenesis to form new blood vessels from existing ones allowing further 
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propagation (McDougall, et al., 2006). In contrast to developmental processes during 
embryogenesis, in adults angiogenesis and vasculogenesis are relatively dormant processes. 
Vasculogenesis is the formation of endothelial progenitor cells that form the interior lining 
of blood vessels (the endothelium), these cells are also used during angiogenesis and are 
heavily implicated in metastasis and the continued growth of tumours (Gao, et al., 2008). 
Angiogenesis in adults is transiently activated for regeneration and wound healing and the 
female menstrual cycle, under normal conditions angiogenic processes are turned "off" and 
tightly regulated.  During tumourigenesis the "angiogenic switch" must become activated 
permanently; the continued formation of blood vessels can supply the increasing metabolic 
requirements of the growing neoplasia (Hanahan & Folkman, 1996). Compounding these 
physiological changes, the precursor cells must acquire invasive capabilities to spread to 
other neighbouring tissues. Modification and loss of cell-cell adhesion molecules (CAMS) 
and cadherins that normally allow cells to bind together and maintain tissue structure 
contribute to the invasive abilities of malignant cells (Tepass, et al., 2000). Upregulation of 
extracellular protease expression and downregulation of their respective inhibitors allow 
invasion across epithelial cell barriers and across blood vessels. These proteases are also 
involved in both angiogenic processes and mitogenic growth signalling which further 
contribute to expansion and invasion (Stetler-Stevenson, 1999). Late-stage metastatic 
tumours display heterogeneity within their cell population; individual cells possess differing 
capabilities for metastasis including no potential at all in a small subset (Kozlowski, et al., 
1984). This heterogeneity results in inefficiency within the metastatic process - only a small 
number of cells are viable (Weiss, 1990). The heterogeneity of the growing tumour is a non-
linear independent process that produces great diversity of potentially metastatic cells 
within the tumour micro-environment; this also results in a reduced effectiveness of 
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biomarker prognoses and therapeutic measures (Kuukasjarvi, et al., 1997). A study in renal 
cell carcinoma shows that metastases can differ almost completely from the primary 
tumour due to multiple severe genomic alterations this indicates that detection of 
metastases based upon the primary tumour's mutations alone is limited (Bissig, et al., 1999). 
These six hallmark features both encourage and are a result of genomic instability from the 
loss of tumour-suppressor genes and other "caretaker" systems that prevent, detect or 
repair DNA damage, as well as activation of proto-oncogenes, lesser fidelity during 
replication or environmental factors providing the correct set of conditions for 
carcinogenesis. The non-deterministic nature of random mutation means the pre-requisite 
mutations and physiological changes can occur at different points and time frames within 
the process not necessarily in the described order - an alternate pathway to cancer but 
ultimately these hallmarks are common in most types of cancer. There are exceptions to this 
theory; in Leukaemia, the leukocytes already possess invasive capabilities as part of their 
function and thus malignant leukocytes do not need to acquire them. 
Recent evidence published by the Cancer Genome Atlas Research network suggests tumour 
progression in clear cell Kidney cancer is further driven by a change in tumour metabolism - 
“Metabolic shift", shifting from one metabolic pathway towards another.  These changes in 
metabolism are also heralded by significant epigenetic changes, both in sporadic and non-
sporadic cases and include mutations within HIF (Hypoxia-Inducible factors) factors such as 
HIF1A and EPAS1. Chromatin modification as a result of frequent mutations in chromatin 
modifier genes in ccRCC (Clear cell renal cell carcinoma) alongside histone methylation 
pathways result in significant changes throughout the tumour furthering its progression. The 
severity and aggressiveness of a ccRCC tumour can be correlated with these shifts in the 
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metabolism of the tumour and the prognosis of the patient (The Cancer Genome Atlas 
Research Network, 2013).  
Birt-Hogg-Dubé Syndrome (OMIM: 135150) is characterised by heterozygous germline 
mutations within the Folliculin (FLCN) gene on 17p11.2 and the disease presents with a 
classic clinical triad of symptoms: Kidney neoplasia, spontaneous pneumothorax and 
fibrofolliculomas (benign skin growths). Approximately 15-30% of patients with BHD present 
with renal tumours (Linehan, et al., 2003); predominantly the histology is that of a 
chromophobe tumour (23% of BHD tumours) or clear cell subtypes, hybrid tumours of 
chromophobe and oncocytoma (epithelial tumours derived from oncocytes noted for a 
granular cytoplasm) are also highly prevalent (Palmirotta, et al., 2010). Chromophobe 
tumours do not stain well and are noted for their pale histology under microscopy, these 
tumours often form in the collecting ducts of the kidney. Chromophobe tumours are distinct 
from "clear-cell" RCC (which account for approximately 70% of sporadic renal tumours) 
which derive from the proximal tubules and stain distinctly (Zhou & He, 2013). BHD 
syndrome displays an age-dependant penetrance, the majority of people with kidney cancer 
are over the age of 55. BHD typically displays no correlation between the type of mutation 
in the Folliculin gene and the phenotype; patients with the same mutations can present with 
disparate phenotypes. However, evidence suggests there may be a phenotype-genotype 
correlation between BHD and colorectal polyps and colorectal cancer  (Khoo, et al., 2002) 
(Nahorski, et al., 2010), in this instance both mutations are on exon 11 at c.1285. Evidence 
suggests allelic heterogeneity of BHD can be a factor in some colorectal neoplasias. The 
syndrome has also been associated with melanoma risk via activation of the mTOR pathway, 
which when unregulated promotes cell growth and melanoma formation. (Toro, et al., 
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1999) (Cocciolone, et al., 2010). There is mounting evidence suggesting a possible 
association with BHD syndrome and an increase risk of Breast cancer syndromes 
(Palmirotta, et al., 2010).  
Fibrofolliculomas (benign skin tumours of the hair follicle usually found on the face), 
trichodiscomas (a related type of benign facial skin tumour) and acrochordons (known as 
'skin tags' are harmless flesh-coloured growths that protrude out of the skin in the neck, 
groin, or armpits) were originally described as the characterising triad of skin manifestations 
that partially define BHD syndrome. Later definitions describe acrochordons as common 
within a population, instead focusing on fibrofolliculomas (FFs) and have been expanded to 
occasionally include angiofibromas (which are more characteristic of tuberous sclerosis), no 
early childhood onset for FFs has been reported for confirmed FLCN mutations (Menko, et 
al., 2009). Fibrofolliculomas have traditionally been classified as benign hair-follicle tumours 
(hence the name) however, recent evidence suggests this classification is incorrect and that 
they are more accurately considered tumours derived from sebaceous glands. It has been 
argued that they represent abnormal differentiation and proliferation from the “sebaceous 
mantle” and progenitor sebaceous gland stem cells driven by abnormal hormonal 
imbalances. This explanation may also aptly explain the noted frequency of FFs in sebaceous 
gland rich areas (For example the nose) over other parts of the skin (Vernooij, et al., 2013). 
Fibrofolliculomas are the most common BHD associated symptom and are found in over 
80% of patients. There have been several studies that suggest an association between BHD 
syndrome and an increased risk of skin tumours - both melanoma and basal cell carcinomas 
however, it has been difficult to demonstrate a direct link between these them (Toro, et al., 
1999) (Khoo, et al., 2002) (Menko, et al., 2009) (Mota-Burgos, et al., 2013). 
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Melanomas are derived from melanocytes –photoreceptors within the skin that secrete 
melanin in response to DNA damage and exposure to UV-radiation which shield 
neighbouring cells from damaging UV rays. Melanocytes are unusual in that they rely on 
external growth factors/mitogens and do not produce their own therefore their 
proliferation is dependent on cell signalling and mitogenic factors produced by other cells. 
Mitogen-Activated Protein Kinases/Extracellular Signal-Regulated Kinase (MAPK-ERK) 
pathways are integral in melanoma progression and are driven by ras oncoproteins. The 
MAPK-ERK pathway activates multiple growth enhancing factors, and is inhibited by Gng12; 
expression of Gng12 is notably decreased in cases of primary or metastatic melanoma 
allowing sustained cell growth by preventing ras inhibition in contrast to upregulated MAPK-
ERK pathways (Byrum, et al., 2013). Malignant melanomas are infrequent skin cancers but 
are aggressive and often metastasize, they are noted for their lethality (Jerant, et al., 2000).  
Basal cell carcinomas (BCC) are among the most common skin cancers; BCCs develop from 
progenitor cells within the basal-skin layer and displays a greater frequency within fair-
skinned or pale individuals. In contrast to a melanoma, a BCC rarely metastasizes and is 
much less dangerous in comparison to a melanoma. Evidence suggests basal cell carcinomas 
use a less efficient energy pathway than a melanoma and are actively hindered by the 
immune system preventing aggressive invasion and metastasis commonly found in 
melanoma; neither neoplasms are under hypoxic conditions.  Within the oxidative 
phosphorylation pathway, the key enzyme in ATP generation responsible for driving this 
pathway is found up-regulated in melanoma but not basal cell carcinomas allowing a greater 
amount of cell activity and aggressively metastatic pancreatic cancers. A lower less efficient 
metabolism and interference from the immune system would explain the much less harmful 
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and invasive basal cell carcinoma despite displaying shared energy pathways and mutations 
with melanomas (Xu, et al., 2012). 
Folliculin (FLCN) is identified as the gene responsible for Birt-Hogg-Dubé syndrome 
(Nickerson, et al., 2002) and is located on chromosome 17p11.2, however its function is 
currently unknown. The Folliculin protein is implicated in energy-sensing and signalling 
pathways such as mTOR (via negative regulation), AMPK and RhoA (Nahorski, et al., 2012) 
(Reiman, et al., 2012). Evidence suggests it acts as a tumour-suppressor gene, albeit 
atypically -whilst bi-allelic inactivation is required for the formation of renal tumours, the 
development of skin nodules and fibrofolliculomas only appear to require inactivation of 
one allele whilst retaining a functional copy resulting in haploinsufficiency (in this context a 
single allele cannot produce enough functional protein by itself to result in a wildtype 
phenotype) (van Steensel, et al., 2007). Recent evidence suggests folliculin protein 
contributes to VHL-mediated suppression of tumour growth similarly to VHL's tumour 
suppression  and autophagy (cell self-degradation during low energy conditions as a survival 
mechanism) regulation activity. This suggests FLCN can contribute towards VHL tumour-
suppression by affecting autophagic processes without mTOR involvement although this 
mechanism is not well understood (Bastola, et al., 2013). Additionally the FLCN homolog 
(dFLCN) in Drosophila when down-regulated resulted in upregulation of rRNA synthesis in 
contrast to overexpression of dFLCN which had the opposite effect, this supports the idea of 
FLCN as a tumour-suppressor showing that it can negatively regulate rRNA (ribosomal-RNA) 
synthesis (Gaur, et al., 2013). There are over 132 known mutations in the FLCN gene; FLCN 
appears to have a hyper-mutatable tract on exon 11, this tract is responsible for 50% of BHD 
mutations in affected families. The majority of these variants are truncating mutations 
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caused by insertions/deletions thus causing a frameshift mutation. This results in the 
premature termination of the FLCN protein which in the absence of nonsense-mediated 
decay, can result in BHD syndrome (Lim et al 2009). These mutations in the FLCN gene are 
detected in 88% of patients with BHD (Toro, et al., 2008); it is possible that the remaining 
12% may be the result of unidentified modifier effects or inadequacies of current diagnostic 
methods and sequencing.  Mutations of Folliculin in sporadic chromophobe renal tumours 
and oncocytic tumours are notably infrequent; this would suggest that tumourigenesis has 
additional pre-requisites in addition to loss of FLCN. Additional mutations and/or 
inactivating mutations are a possible aetiology (Nagy, et al., 2004); furthermore FLCN shows 
a wide expression profile across various tissues. FLCN mRNA shows high expression in most 
tissues yet displays reduced expression in cell types typically associated with the disease 
phenotype, namely skin, lung and kidney tissues. These findings are consistent with the idea 
that FLCN functions as a tumour-suppressor in renal cancers (Warren, et al., 2004).  
Whilst BHD is known to display age-dependant penetrance; the lack of a phenotype-
genotype correlation may suggest that modifier alleles and epistatic mechanisms play a 
significant role in the development of the BHD phenotype. There is a precedent for this in 
Von Hippel-Lindau syndrome (OMIM: 193300, henceforth known as VHL), another familial 
cancer syndrome with an autosomal dominant inheritance. VHL is a tumour suppressor 
gene which predisposes to multiple neoplasms most notably Renal Cell Carcinomas (RCC). 
Mutations of VHL have been reported to be in up to 75% in sporadic Clear Cell RCC (ccRCC). 
VHL is also responsible for other malignant and benign tumours affecting other organ 
systems such as pancreatic tumours and cysts, phaeochromocytomas and 
haemangioblastomas (Foster, et al., 1994) (Gnarra, et al., 1994). Contrary to Birt-Hogg-Dubé 
Page | 17 
 
syndrome, VHL displays phenotype-genotype correlations (Pavlovich & Schmidt, 2004). 
Epigenetic silencing can be a more prevalent cause compared to somatic mutations in some 
tumour suppressor genes.  Methylation and other epigenetic repression are implicated as a 
factor in sporadic VHL, hereditary non-polyposis colorectal cancer, breast and ovarian 
cancer (Banno, et al., 2012). Hypermethylation of the CpG islands in the VHL tumour-
suppressor gene was found to result in inactivation of VHL in Renal Cell Carcinoma tumour 
subsets consistent with this model (Herman, et al., 1994). CpG islands are cytosine and 
guanine rich sites common in mammalian promoter regions found in up to 40% of genes 
(Fatemi, et al., 2005), they are methylated age-dependently (Banno, et al., 2012). Such 
methylation is capable of acting as the “second-hit” for tumourigenesis progression in 
inherited cancer syndromes as defined using Knudson’s Two-hit model. Inactivation of the 
second allele of a vital tumour-suppressor gene, a “Loss of Heterozygosity” is a major event 
in initiating and driving tumourigenesis.  Atypical promoter methylation results in epigenetic 
silencing and a loss of expression. In the context of a tumour-suppressor gene this provides 
a clonal advantage, mirroring the selective advantage beneficial mutations might provide a 
cell or organism. Naturally this results in a positive feedback effect, predisposing to 
additional changes within that cell population both genetic and epigenetic. (Baylin & Ohm, 
2006). Clonal Expansion of this nature has been found in multiple cancer types, including the 
Kidney (Bardessy, et al., 1995). There is evidence of this occurring in von Hippel-Lindau 
syndrome (Prowse, et al., 1997); it is possible that this may also occur in Birt-Hogg-Dubé 
Syndrome. There is significant evidence to suggest that passenger deletions can occur to 
surrounding genes during a homozygous deletion of a tumour-suppressor gene, resulting in 
ancillary functional losses. It has been estimated that up to 11% of coding genes responsible 
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for the production of proteins are lost in this manner in human cancers (Muller, et al., 
2012).  
Loss of heterozygosity and Methylation of the promoter regions in Folliculin are more 
prevalent causes of inactivation in sporadic BHD cases in contrast to somatic mutation 
(Khoo, et al., 2003). In an investigation of the involvement of Folliculin in primary sporadic 
RCC and colorectal cancers, several pathogenic somatic FLCN mutations were found. 
Inactivation of BHD in sporadic clear-cell RCC only occurred in a subset of samples. In 
addition an absence of epigenetic silencing of FLCN was detected in multiple patients 
alongside a lack of hypermethylation of promoter regions in primary RCC patients. 
(Fernandes da Silva, et al., 2003). FLCN promoter methylation and SNPs associated with 
modifying risk of a certain phenotype (Single Nucleotide Polymorphisms are variations that 
don't have a major effect on gene function in contrast to a mutation) are demonstrated to 
have an effect on tumour suppression alongside TP53 in sporadic chromophobe Renal Cell 
Carcinomas (Gad, et al., 2007). A recent study has further associated VHL with BHD 
syndrome, demonstrating a direct connection between FLCN tumour-suppression in VHL 
and autophagy regulation. This is further supported by the ability of VHL to suppress HIF 
factor activity, necessary for autophagic processes. In clear-cell RCC cells with VHL loss, 
lower levels of FLCN proteins can be detected even without mutations present within FLCN 
suggesting further interaction between VHL and FLCN. Clear-cell RCC can be considered a 
sub-type of BHD-related cancer so these findings are of particular interest; it has been 
suggested microRNAs produced by VHL might affect or repress translation of FLCN proteins 
(Bastola, et al., 2013). 
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This study focuses on the potential modifier effects that might influence and predispose to 
specific phenotypes within BHD syndrome and the genetic events implicated in renal 
tumourigenesis in BHD and sporadic renal tumours. Germline genetic variations Single 
Nucleotide Polymorphisms that can affect cell structure, growth or regulation can 
predispose an individual to specific cancers and can also modify the risk of cancer in patients 
with inherited cancer syndromes. Thus germline Single Nucleotide Polymorphism (SNP) 
variants of the BRAF gene were identified as predisposing males risk by up to 4% to 
malignant melanomas. This increase is greater than the risk conferred by the known 
melanoma susceptibility locus for CDKN2A (codon 599 - V5993 on exon 15) increases risk of 
melanoma cases by less than 1%. CDKN2A mutations are detected and associated with 
approximately 25% of familial cases of melanoma. Germline BRAF SNPs are more commonly 
found in the population than somatic CDKN2A mutations. (Meyer, et al., 2003). Whilst the 
individual risk per variant might not be significant on its own in combination with other 
variants their cumulative increase of neoplasms can be significant. SNPs tend to result in a 
relatively small increase in risk but are far more common within a given population in 
comparison to an inherited susceptibility mutation. Recently there have been studies 
investigating other modifiers in Renal Cell Carcinoma; in particular a study by Vahteristo 
used a genome-wide linkage analysis to compare loci between RCC and Hereditary 
Leiomyomatosis (HLRCC) (Vahteristo, et al., 2010). No evidence for a genetic modifier was 
found in those loci however the study did not refute the existence of potential modifiers in 
RCC. Evidence suggests the SNPs within CCDN1 (Cyclin D1) modifies risk in germline VHL 
tumour expression alongside HIF-independent mechanisms (Zatyka, et al., 2002). CCND1 
and its hypoxia-inducible factor (HIFs) have also been associated with a susceptibility locus 
at 11q13.3 in renal cancer which is covered in detail in a later section (Schödel, et al., 2012). 
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Germline SNPs in several genes (including MMP1, MMP3 and VEGF) have been 
demonstrated to act as modifiers for RCC risk for sporadic and familial VHL disease (Ricketts, 
et al., 2009).  
 Modifier effects have also been studied in other familial cancer syndromes; variants within 
the promoter region of BRCA1 contribute to risk of familial breast and ovarian cancer risk 
(Bielinksa, et al., 2013). Another study found a modifier locus at 6p24 specific to women 
carrying BRCA2 mutations that modified breast cancer risk but had no effect on patients 
with BRCA1 mutations or the general population (Gaudet, et al., 2013). Several low 
penetrance alleles have been studied and linked to familial breast cancer, no link was found 
between these SNPs and sporadic breast cancer cases (Cardeñosa, et al., 2012). 
Aims: 
The aim of this study was to further investigate the marked Phenotype-Genotype variability 
displayed in Birt-Hogg-Dubé syndrome, in particular to investigate candidate modifier alleles 
for potential effects on skin and tumour risks in BHD syndrome. In addition, tumourigenesis 
is a multistep process and although inactivation of FLCN is the first step in renal 
tumourigenesis in BHD syndrome, other genetic events occur. To date the nature of the 
alterations and how they compare to those in sporadic RCC has not been identified. The two 
elements of my MPhil studies were: 
1) To analyse polymorphic variation at candidate modifier genes in 70 BHD patients 
DNA to see if there is any correlation between the genotypes at these loci and the 
patients' phenotypes. 
2) To undertake bioinformatic analysis on exome data from two BHD renal cancers and 
then analyse additional sporadic RCC tumour DNA samples to determine whether 
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genes implicated in BHD renal tumourigenesis might also be implicated in sporadic 
RCC. If common somatic mutations occurred in specific genes in both BHD and 
sporadic RCC then those genes could be considered as candidate modifier genes for 
risk of developing kidney cancer in BHD patients.  
Selection of Polymorphic variants: 
To select which alleles might be implicated as Modifier Alleles a literature search was 
performed through recent and relevant studies. The selection criteria for relevant 
polymorphisms included: frequency of allele in the population, the nature of association 
with a relevant characteristic of BHD (melanomas, neoplasia risks) the calculated relative 
risk and P-value of the polymorphism in the study. The odds ratio measures the association 
of an outcome such as increased risk of a specific disease versus the 'exposure' which in this 
context refers to medical history or specific health factors. An odds ratio of greater than 1 is 
associated with a higher risk of the outcome (a disease phenotype) and conversely an odds 
ratio less than 1 results in a lower likelihood (Szumilas, 2010). The following eight 
polymorphisms were selected to analyse. 
ASIP (rs4911414[T] and rs1015362[G]) 
Variants rs4911414[T]and rs1015362[G] are alleles of the ASIP gene (Agouti-signalling 
protein) which is associated with the production and regulation of melanin pigments and is 
known to bind to MC1R (Kanetsky, et al., 2002). Both rs4911414  and rs1015362 are known 
to consistently modulate melanoma risk in tandem and show an association with a fair skin 
colour and increased melanoma risk (both present with an OR of 1.45, P-value of 1.2x10-9) 
even after adjusting for MC1R variants (Nan, et al., 2009).  ASIP is known to affect specific 
pigmentation traits in humans such as the skin, eye and hair pigmentations. It is also 
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associated with a multitude of pleiotropic manifestations such as diabetes and obesity.  
Evidence suggests ASIP does not contribute to pigmentation via the same mechanisms as 
MC1R (Voisey, et al., 2002) but that polymorphisms in non-coding regions might result in 
loss of function. ASIP is an antagonist ligand that results in a less protective yellow form of 
melanin - phaeomelanin (rather than the darker eumelanin) by inhibiting MC1R receptors 
(Voisey, et al., 2003). 
ASIP displays a strong association with increased risk of cutaneous melanomas and basal cell 
carcinomas (BCC) with a combined P-value of 1.2x10-9 (Gudbjartsson, et al., 2008). 
MC1R rs1805007 [T] 
MC1R (Melanocortin-1-receptor gene) is a highly polymorphic gene that encodes 
melanocyte-stimulating hormone (MSH) which regulates melanin pigment production 
(Melanogenesis).  The gene is a risk factor for melanomas and plays a significant role in 
pigment variation in humans. Red hair, fair skin and ultraviolet radiation sensitivity are 
strongly associated with the MC1R gene (Perez Oliva, et al., 2009). Melanocortin-1-receptor 
mutations are common in European populations and are responsible for an increase of 
Melanoma risk.  It is a known modifier of risk in CDKN21 mutants, which are lower 
frequency but higher penetrance mutations that confer a greater risk. In combination with 
CDKN2A the penetrance of mutations increased significantly by 84% with a mean onset age 
of 37.8 years (Box, et al., 2001).  ASIP variants modify the risk of melanoma and basal cell 
carcinoma when interacting with MC1R (Gudbjartsson, et al., 2008).  The rs1805007 variant 
(T allele) was found to have the highest Basal Cell Carcinoma risk with an OR of 1.55 and a P 
value of 5.9x10-9 ; it is known to be a red hair colour variant (Nan, et al., 2011). The 
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rs1805007 and rs1805008 variants are common non-synonymous mutations in European 
populations and have a discernible effect on pigmentation (Makova & Norton, 2005).  
Variants of MC1R are also known to significantly increase the risk of melanoma in a Latvian 
population (Ozola, et al., 2013) and the phenotype displays a "gene dosage" effect - carriers 
of multiple variants display a greater vulnerability. Evidence suggests there is a secondary 
mechanism for modification of melanoma progression and risk induced by MC1R variants 
that is unrelated to pigmentation (Robinson & Healy, 2002) or it may negate the protection 
provided by darker pigmentation. This mechanism would help account for discrepancies 
noted in previous research showing increased melanoma risk attributed to specific variants 
even when melanoma-associated phenotypes such as fair skin and red hair are not present 
or otherwise accounted for (Valverde, et al., 1996) (Palmer, et al., 2000). Both MC1R 
variants have been suggested to have been driven by recent positive selection; this might 
suggest these alleles confer an adaptive beneficial trait (Sulem, et al., 2007). One hypothesis 
for the benefits involved the fairer skin in European populations allows for increased 
production of vitamin D in the skin reducing the risk of vitamin D deficiency and ricketts, 
however there is not enough statistical evidence to support this claim (Rana, et al., 1999). 
Alternatively it has been argued MC1R is neutrally selected and the high polymorphic rate in 
European populations is due to the "relaxation of constraints" outside of Africa as these 
variants are likely more deleterious in African climates (Harding, et al., 2000), this does not 
discount the possibility of diversifying selection however. 
TYR rs1126809 (R402Q) 
Tyrosinase (TYR) located on 11q14-21 is the gene responsible for the conversion of the non-
essential amino acid tyrosine into Melanin via the enzyme tyrosinase. TYR is 
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transcriptionally regulated by Microphthalmia-associated transcription factor (MITF); a 
family with a heterozygous single base pair deletion in MITF were also found to bear the 
R402Q polymorphism and presented with features consistent with occular albinism and 
Waardenburg syndrome (Morell, et al., 1997). Polymorphisms within this gene can be 
attributed to common melanoma risk factors such as freckling and UV sensitivity (Bishop, et 
al., 2009). (Gudbjartsson, et al., 2008) Found that the TYR rs1126809 (A) variant is known to 
affect eye colour and tanning increased the risk of both Cutaneous Melanoma (OR 1.21, P = 
2.8x10-7) and Basal Cell Carcinoma (OR 1.14, P=6.1x10-4). This variant is sometimes referred 
to as R402Q/1205 G> A this nomenclature describes the amino acid change from arginine 
(R) to a glutamine (A) at position 402. Eye colour, specifically blue, is known to be a risk 
factor for melanomas independent of skin pigmentation and nevi count (Bliss, et al., 1995). 
The A allele of rs1393350 has a strong association with the rs1126809 SNP and blue eye 
colour (Sulem, et al., 2007) (Allwood & Harbinson, 2013). The rs1393350 variant has also 
been implicated in melanoma risk with a significance of 2.41x10-14 (Bishop, et al., 2009). 
R402Q is also found to significantly increase the risk for squamous cell carcinoma (SCC) as 
well as melanoma risk (Nan, et al., 2009). Despite the involvement with pigmentation 
mechanisms, the TYR rs1126809 variant bears no association with autosomal recessive 
ocular albinism (Oetting, et al., 2009) contradicting previous findings (Hutton & Spritz, 
2008). However, other mutations in TYR are responsible for oculocutaneous albinism type 1 
(Ray, et al., 2007). This discrepancy might be resolved with suggested genetic disequilibrium 
with R402Q - non-random allele association at different loci resulting in a greater population 
frequency than might be expected through random chance. R402Q substitution is 
demonstrated to have an effect on the thermo-sensitivity of the protein in albino mice 
within the ribosome functioning normally at 32 °C  transporting melanosomes however at 
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37°C the protein was shown to misfold and co-localised within the ribosome suggesting a 
possible mechanism for affecting melanoma risk (Halaban, et al., 2000). 
MITF rs149617956 (E318K) 
MITF (Microphthalmia-associated transcription factor) is implicated in melanocyte 
development and differentiation of other cell types. MITF regulates TYR expression and 
protein levels by binding to the promoter region. A recent study demonstrated that MITF 
controls pancreatic β cell function via direct regulation of Pax6 transcription; Pax6 is also 
known to be involved in pigment cell differentiation (Mazur, et al., 2013) . The E318K variant 
was strongly associated with melanoma risk in two independent studies, in both an 
Australian sample group and a British group. With the British and Australian cases 
combined, the presence of this MITF variant had an OR of 2.19 and a two-sided P value of 
0.0003. Notably this variant was also associated with eye colours, specifically non-blue as 
well as an increased naevus count (“birthmarks”). These features may contribute towards a 
phenotype that can be associated with the variant most associated with melanoma risk, 
although linkage and Genome-Wide association studies have had difficulty proving so 
(Yokoyama, et al., 2011). In the UK sample Yokoyama et al noted the extremely low 
frequency of the "A" allele compared with the G/G genotype, the "A" allele had a frequency 
of 0.009 in affected patients and a frequency of 0.004 in the control samples. Due to the low 
frequency of the deleterious allele that it would be harder to implicate it as a causative 
factor especially in small sample size studies.  The phenotypic associations are in contrast to 
MC1R and TYR which increase risk in association with “fair skin” traits. Previously MITF has 
been identified as a melanoma oncogene when amplified, leading to greater mortality rates 
in patients and was more prevalent in metastatic disease (Garraway, et al., 2005). 
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Furthermore, MITF is frequently found mutated or over-expressed in certain melanoma 
subtypes (Cronin, et al., 2009).   
11q.13.3 loci (rs7105934) 
A genome-wide association study found an uncommon polymorphism (rs7105934) located 
on locus 11q13.3 that is implicated in increased renal cell carcinoma (RCC) risk; this locus 
has no characterised genes. The variant rs7105934 displays an OR of 0.71 and a p-value of 
7.8x10-14 (Purdue, et al., 2011). Risk of renal carcinoma is reduced by 0.69 times when the 
[A] allele is present, this protective effect seems to be lost or reduced in heavy 
smokers/drinkers or overweight people. The locus lacks CpG islands which are typically 
associated with promoter regions, these "Islands" are rich in cytosine and are indirectly 
methylated as a form of epigenetic regulation (Saxonov, et al., 2006). Methylation of CpG 
islands in contrast to CpG sites can occur up to 2 kilobases away at highly conserved regions 
that are termed "CpG island shores” (Irizarry, et al., 2009). In addition to the genome-wide 
association study, it has also been found that the rs7105934 variant is known to modify RCC 
risk in a Chinese population (Cao, et al., 2012) with the caveat that additional population 
studies may be required to validate these findings.  The 11q13.3 locus has also been 
implicated in other human cancers, the rs11228565[A] allele is associated with increased 
risk of prostate cancer (Gudmundsson, et al., 2009). The locus is commonly amplified in a 
multitude of cancers including human breast cancers (Lundgren, et al., 2008) and is flanked 
by genes overexpressed in various cancers such as CCDN1 which is responsible for cell-cycle 
regulation via encoding cylcin D1 proteins (Turnbull, et al., 2010). rs7105934 is now known 
to regulate hypoxia inducible factor (HIF) binding using a cyclin D1 transcription enhancer, 
this can result in a loss of cell-cycle regulation. Evidence suggests this locus contains a long-
range HIF-dependant transcriptional enhancer, this enhancer is coupled with the CCDN1 
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promoter which then disrupts HIF binding and hypoxia pathways (Schödel, et al., 2012). 
CCDN1 is an oncogene activated by mitogenic deregulation, copy number alterations or 
infrequently by mutation. The role of Cyclin D1 as a commonly dysregulated oncogenic cell 
cycle regulator is well known; deactivation of cyclin expression  result in the characterised 
hallmarks of cancer discussed previously and is therefore a potential therapeutic target and 
biomarker (Musgrove, et al., 2011).  
EPAS1 rs11894252 
The Endothelial PAS Domain containing protein 1 (EPAS1) is located on chromosome 2p21, 
this gene is known to encode transcription factors that induces genes regulated by low 
oxygen levels in the cell (Hypoxia) known as Hypoxia-inducible factors (HIF). HIF factors are 
highly conserved and are essential during development; they can also promote angiogenesis 
in tumours and other survival factors during hypoxic conditions. HIF factors are commonly 
upregulated in VHL syndrome as a consequence of mutation to the VHL suppressor proteins 
(Maina, et al., 2005); overexpression of HIF factors increases the amount of  mRNA involved 
for angiogenesis, energy metabolism and apoptotic pathways during hypoxic conditions as a 
result EPAS1 is a key gene for RCC development. EPAS1 causes increased angiogenesis in 
RCC by upregulating Vascular endothelial growth factor (VEGF) in tumour tissue; both EPAS1 
and VEGF mRNAs shown co-expression and are present at significant levels in RCC (Xia, et 
al., 2001). These HIF factors are a suggested therapeutic target; normal oxygen dependant 
regulatory processes resume with the reintroduction of pVHL into the tumour (Zimmer, et 
al., 2004). The EPAS1 variant rs11894252 located on intron 1 has been shown to increase 
RCC risk (combined OR 1.14, P value of 1.8x10-8), it was noted the risk was significantly 
higher in smokers than non-smokers (Purdue, et al., 2011). The apparent differences in risk 
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between men and women (higher in men) have been mostly attributed to the 
aforementioned frequency of smoking however; additional confirmation may be required.  
MMP1 rs1799750 (G/G) 
Matrix Metallopeptidase 1 (Interstitial Collagenase) hence force known as MMP1 is a gene 
in the MMP gene cluster located on chromosome 11q22.3. The proteins known as matrixins 
produced by this gene are zinc-dependent proteases that degrade extracellular molecules, 
as a result MMP genes have critical roles in angiogenesis, apoptosis, cell proliferation and 
differentiation and can drive in vivo tumourigenesis (Foley, et al., 2013). A link has been 
found in MMP1 mRNA expression between smokers and non-smokers using buttock skin 
artificially exposed to UV radiation, concluding that tobacco smoking exacerbates ageing 
effects by inducing MMP1 expression especially in combination with ultraviolet radiation 
(Lahmann, et al., 2001). rs1799750 is an insertion polymorphism occurring at position -
1607bp located in the MMP1 promoter, the G/G germline polymorphism is attributed to 
increased risk in a multitude of cancers. It has been shown to increase risk in ovarian cancer 
(Kanamori, et al., 1999), colorectal cancer metastasis (Ghilardi, et al., 2001),  breast cancer 
(Hughes, et al., 2007), lung cancer - especially in men and non-smokers (Su, et al., 2006), 
chronic obstructive pulmonary disease (Wood & Stockley, 2006), chronic kidney disease 
(Yoshida, et al., 2009) and rheumatoid arthritis onset as a result of polymorphisms in VEGF 
and MMP1 (Chen & Mattey, 2012).  The rs1799750 (2G) variant was determined to have a 
greater frequency in Renal Cell Carcinoma patients in a Japanese population than 
population controls might suggest  (Hirata, et al., 2004) with an OR of 1.95 CI 1.31-2.91. 
These findings have been independently verified, with MMP1 2G polymorphism being 
significantly associated with RCC risk confirming the role of MMP1 and MMP3 in as 
susceptibility and risk factors in both familial and sporadic cases. These findings provided an 
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OR of 1.49 with a 95% CI 1.06-2.08 and a P value of 0.017 (Ricketts, et al., 2009).  A recent 
study determined that by silencing NEU3 (human plasma membrane sialidase enzyme) in 
RCC its malignancy could be reduced; the silencing resulted in downregulation of MMP1 and 
MMP7 alongside blocking autophagy and inducing apoptosis  using the  β1 integrin-recycling 
pathway  (Tringali, et al., 2012). This further underscores the role of MMP1 in RCC 
development and pathogenesis. 
Investigating mechanisms of tumourigenesis in BHD syndrome: 
Previously studies in RCC from BHD syndrome have demonstrated somatic FLCN mutations 
consistent with a "two-hit" model of tumourigenesis in patients with germline FLCN 
mutations (Vocke, et al., 2005). However, most examples of human tumourigenesis 
represent a multistep process and there was no pre-existing information on what additional 
somatic mutations might be implicated in the development of a renal tumour in BHD 
patients. 
For the second part of the project I had access to exome sequencing data of normal tissue 
and a kidney tumour from a patient with BHD syndrome who, unusually, had also developed 
two gastrointestinal tract tumours. I analysed the exome data to identify candidate somatic 
mutations and then proceeded to validate these in the BHD tumour and then investigated 
whether relevant genes were mutated in sporadic non-BHD tumours.  Exome sequencing 
data from a second BHD tumour from a Japanese patient with classical BHD syndrome was 
also investigated to see if there were any common mutations between these two tumours.  
Exome sequencing is a more targeted and cost-effective method of sequencing and 
analysing potential mutations and causative agents for diseases; especially those that 
display Mendelian inheritance (single locus inheritance in contrast to diseases caused by 
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multiple gene interactions or loci) by sequencing only the exons of a patient or the "Exome." 
The significance of the exome is in understanding the functional changes caused by variation 
within the exons - the coding regions within a gene whereas full genotyping studies also 
sequence intronic (non-coding) regions (Ng, et al., 2009).  The effectiveness of exome 
sequencing in identifying causes of single gene disorders has already been demonstrated in 
Miller syndrome (OMIM: 263750); a rare autosomal recessive disorder that often results in 
cleft palate deformations, supernumerary nipples and micrognathia (Ng, et al., 2010). As 
exons make up 1% of the genome and untranslated regions are often not included, exome 
sequencing is limited to only finding variation on coding-regions and only variants which 
that can affect the function of proteins produced by the gene. Non-coding or structural 
changes that contribute towards a disease phenotype cannot be found through exome 
sequencing but instead through whole genome sequencing.  However, one estimate 
suggests that exons contain 85% of deleterious causative mutations that significantly affect 
a disease phenotype (Choi, et al., 2009).  Statistical errors such as false positives and 
negatives are always a problem when generating large amounts of data such as from 
extensive sequencing via exome/genome techniques however there are methods to reduce 
these problems. 
Exome sequencing is but one tool used in the Cancer Genome Project - an ongoing initiative 
to identify somatic mutations and variants that are crucial during the acquisition and 
development of cancer syndromes. The project by the Sanger Institute uses genome-wide 
analyses and detection to determine critical mutations within tumours using a variety of 
sequencing methods whether genome, exome or transcriptome (Wellcome Trust Sanger 
Institute, 2013). This effort has already identified several common mutations and a second 
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major ccRCC gene (PBRM1) within RCC using exome sequencing (Varela, et al., 2011). The 
strength of a cancer-genome study has been demonstrated in malignant melanoma showing 
a predilection for DNA repair processes towards the transcribed regions within a gene over 
other areas, allowing a wide distribution of acquired mutations over time (Pleasance, et al., 
2010). 
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Methods and Materials 
Patient Samples 
Patient blood and tumour samples were acquired from patients diagnosed with Birt-Hogg-
Dubé syndrome or sporadic RCC (detailed information on age at diagnosis and other clinical 
characteristics of the patients was not available to me).  
Written informed consent had been obtained from all patients and the study had been 
approved by the South Birmingham Research Ethics Committee. 70 patient samples in total 
were analysed.. After extraction of DNA by standard methods, the samples were aliquoted 
in 10µl aliquots and kept as stock solutions in -20°C cold storage. From these solutions, the 
'working solutions' were made on a sealed  a Star Lab 96 well PCR plate using an assumed 
concentration of 500ng/µl diluted to 20mg/µl, then made up to 100µl per sample. The plate 
was sealed using Thermo Scientific Adhesive PCR lids and also stored at -20°C. From this 
plate 1µl of diluted DNA would be extracted and added to each PCR plate in conjunction 
with the appropriate primers.  
Primer Design 
Primers for both stages of the experiment were designed using Primer3 online software 
with a desired optimum melting temperature of between 58°C and 60°C depending on the 
sequence. Primer 3 can be found at "www.frodo.wi.mit.edu" alongside documentation of 
how the software works (Rozen & Skaletsky, 2000). Care was taken to ensure whenever 
possible that primers had a similar melting temperature (TM) and annealing temperature 
between pairs and each other as this would allow for greater efficiency by running multiple 
different primers on the same PCR machine.  The GC content (amount of Guanine-Cytosine 
pairs within a sequence affect the melting temperature as G-C bonds use a triple hydrogen 
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bond compared to A-T's double bond, as a result more energy is required to break this 
bond.) was carefully monitored during the design stage. Each oligonucleotide was designed 
to encompass a region of approximately 500 base pairs (bp) long to provide enough room 
around the polymorphic site of interest to ensure artefacts created by the sequencing 
process would not overlap the polymorphism.  This was to ensure the sequence in question 
would be as clear as possible. The oligonucleotides themselves were designed to be 20bp 
long allowing for enough specificity to bind to the target region. The primer3 software 
automatically chooses regions within a sequence that are less likely to bind to themselves or 
to the complementing primer within the mixture forming a distinctive "primer-dimer" when 
amplified. The oligonucleotides were then ordered from Invitrogen Lifesciences with a 
synthesis scale of 25nmol, desalted purification and with no additional modifications.    
Primer Handling and Storage 
The primers were then diluted using purified water, to 200pmol/µl using the given 
concentrations that came with the primers to create a stock solution.  These stock solutions 
were stored in the -20°C freezer. From these stock solutions a "working solution" could be 
created using a 1 in 10 dilution; the use of a working solution has multiple advantages. First 
it reduces the risk of contamination of all subsequent primer solutions by reducing the 
number of times the "stock solution" is opened and closed. Secondly it allows for further 
control over the dilution of the primer solution without affecting the stock and thirdly 
oligonucleotides are susceptible to frequent temperature changes - by freezing and thawing 
constantly the sequences might become damaged or unreliable. These measures ensure 
that the  stock solution of each primer is kept as sterile and stable as possible, if a working 
solution becomes contaminated it the problem can be identified easier and can be replaced 
more easily.  
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Polymerase Chain Reaction 
Each time a set of DNA samples were to be tested for polymorphisms a "master-mix" was 
created, all components were mixed together into a bulk solution in an eppendorf then 
aliquot onto a 96-well PCR plate with the sample configuration recorded for later 
identification. The individual chemicals were kept on ice whilst the mixture was being made. 
The contents of the master-mix were as follows: 
Table 1 PCR reagents 
"Master Mix" components, made up to 50µl per Sample. 
Component Volume per Sample (µl) 
Buffer (with magnesium) 5 
dNTPs 1 
Forward Primer 1 
Reverse Primer 1 
Taq Polymerase 0.2-0.4 
Purified Water 40.8 
 
The Taq polymerase was always the last reagent to be added and was kept on ice the entire 
time.  Once the solution had been made the eppendorf containing the master-mix would be 
vortexed using a Biocote Vortexmixer for a minimum of 3 seconds so the contents would be 
evenly dispersed within the eppendorf. If this step were not taken it is possible a differing 
amount of each component would be present in each subsequent aliquot which could affect 
the quality of the PCR and prevent some wells from amplifying at all. After 49 microlitres of 
the mastermix were aliquoted into each well using a Gilson pipette, 1µl of the patients' DNA 
sample would be aliquot from the frozen "working solution" of patient DNA into the 
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relevant well. Extra care was taken to avoid cross-contamination and ensure throughout the 
process that any reagent or sample was correctly aliquot into the well, when adding the 
DNA it was done by eye to observe the sample going into the solution rather than adhering 
to the side of the wells within the plate. After this the PCR plate would be sealed up with a 
Thermo Scientific adhesive lid; the seal would be manually checked and firmly wrapped 
around the PCR plate ensuring it was evenly covering the plate with no room for 
evaporation to escape the plate whilst being amplified. Once the lid was secure, the PCR 
plate was inserted into a Biometra Basic T professional PCR machine. The following program 
was run: 
Table 2 PCR protocol 
 Polymerase Chain Reaction (PCR) Protocol 
Step Temperature (°C) Length (Minutes:Seconds) Go To Loops 
1 95 00:30 (Pre-heating)   
2 95 00:30 (Denaturation)   
3 58-60 00:30 (Annealing)   
4 72 00:45 (Extension) 2 40 cycles. 
5 72 07:00 (Extension)   
6 12 Pause (Holding Step)   
 
The protocol described in Table 2 contains a pre-heating step to 95°C, after this a 
denaturation-annealing-extension cycle would be replicated forty times before a final 
extension step lasting 7 minutes. After this the program would transition to a cooling and 
storage step for when it cannot be manually moved to storage. The temperature in step 3 
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(the annealing step) is listed as a range; this temperature is changed depending on the 
melting temperature (TM) of the primers used. 
Following this step the plate would either be stored within the PCR machine during the 
cooling step or transferred to a fridge in preparation for the next step. 
Agarose Gel Electrophoresis: 
After the plate was amplified within the PCR machine it was important to confirm 
amplification was a success, therefore testing the samples by running a gel was necessary. 
10 µl of each PCR product were transferred using a pipette to a secondary plate for transfer 
in addition to 5µl of a "loading dye". 
The Gel was created using 1.5g of agarose powder  dissolved in 150ml of TBE (Tris Acetate 
EDTA)  buffer creating a 1% solution. This solution was heated in a microwave for 
approximately 2 minutes until the solution became clear to the naked eye. The bottle was 
then cooled down using tap water around the outside of the bottle until it was comfortable 
to hold, this takes a minute or more to cool down in this manner. The significance of this 
step was 1) safety 2) so as not to damage the Gel trays by constant heating and cooling and 
3) so it would be cool enough to add in ethidium bromide and reduce the risk of ethidium 
bromide vapours being released. After the bottle was cooled sufficiently 0.5µl of Ethidium 
Bromide  was added to the solution using a pipette, this functions as a fluorescent tag 
within the solution once exposed to Ultra-violet light (UV) to visualise the DNA. The bottle 
was then shaken to make sure the Ethidium bromide was properly mixed, after this it was 
poured into a gel tray and left to cool for 20-30 minutes, "combs" were inserted into the 
cooling solution allowing for "wells" to be created for the next step.       
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Once set the gels were inserted into an electrophoresis tank (Geneflow water bath) 
submerged in TBE buffer; 15µl would be transferred into the wells created by the combs 
using a pipette. The contents of each well were documented for later reference and the lid 
was placed onto the tank. A voltage of 180-200 was run through the gel after checking the 
correct alignment of the gel so the gel runs forwards not backwards across the current.  
After 15-20 minutes the gel would be removed from the tank and carefully inserted into a 
Syngene UV transilluminator.  Where it would be exposed to UV light and a photograph of 
the gel would be taken. 
The gels would be checked for bands of amplification with a similar product size predicted 
by the Primer design; any "Primer-Dimer" formations would be noted as a failed 
amplification. Whilst the primers were designed to avoid "Primer-Dimer" it was still possible 
for it to occur.  Any samples that had successfully amplified were stored in the fridge 
alongside the original 96-well PCR plate so if a problem occurred it would be possible to 
reuse spare PCR product to retry later steps. 
"Exosap" clean up phase: 
The successful amplicons were recorded and a new 96-well plate was set-up for a cleaning 
and sequencing preparation stage.  Exosap refers to Exon Nuclease I a reagent that 
improves the quality PCR products by removing the primers not used up in the PCR 
amplification step whilst the "Shrimp Alkaline Phosphatase" removes any remaining dNTPs 
(Nucleics, 2013).  A new mastermix was created for this stage: 
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Table 3 “Exosap master mix” Reagents 
"Exosap Master Mix" components to 10µl per Sample. 
Exon Nuclease I 0.25µl 
Antarctic Phosphatase 1µl 
Antarctic Phosphatase Buffer 1µl 
Water 1.75µl 
 
The exosap master-mix was vortexed so the contents would be thoroughly mixed. 
6µl of the previous successful PCR products were added to the 96-well plate, whilst 4µl of 
the exosap was carefully pipetted into the well taking care to ensure no product was 
adhering to the sides of the well so that both the exosap and the product could mix. The 
plate was tightly sealed with a thermoplastic lid before being placed inside the Biometra. 
The following "Exosap" protocol was run:  
Table 4 Exosap Protocol 
Exosap Protocol 
Step Temperature (°C) Length (Minutes:Seconds) 
1 37 30:00 
2 85 15:00 
3 4 Pause 
 
Afterwards the plate was stored in a fridge in preparation for the next step. 
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The Sequencing Reaction: 
For each successful amplicon that had been exosapped; a "forward" and "reverse" well was 
set up on a fresh 96 well plate and two "master-mixes" were created: 
Table 5 Sequencing Reaction Reagents 
Sequencing reaction 6µl per Sample. 
"Big dye" 0.75µl 
5X Sequencing Buffer 2µl 
Forward Or Reverse Primer 1µl 
Water 2.25µl 
 
One master-mix would use the Forward primer only and the other would use the Reverse 
primer only, keeping them separate. In the interests of efficiency multiple successful 
amplifications of the same polymorphism would be done together so any samples within 
that set that worked could be pooled together onto one plate. This also attempts to reduce 
the risk of cross-contamination between different sets or primers, samples and 
polymorphisms. "Big-Dye" improves the quality of sequencing, but is susceptible to 
repeated freeze-thaw cycles; therefore it must be aliquoted  into smaller working samples. 
In addition it must be allowed to thaw at room temperature then stored "on-ice" whilst 
creating the master-mix, as a sequencing dye it is light and UV-sensitive and must be kept 
wrapped in tinfoil and kept away from windows or lights whilst in use (Applied Biosystems, 
2010). These solutions would be vortexed allowing for the reagents to thoroughly mix; then 
6µl would be pipette into each well with the forward and reverse solutions kept separate 
and adjacent. 4µl of the exosap samples would then be pipette into each relevant well both 
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in the forward and reverse wells. After this the plate would be sealed once more using a 
thermoplastic lid and run in a PCR machine using the following protocol: 
Table 6 Sequencing Reaction Protocol 
 Sequencing Reaction Protocol 
Step Temperature (°C) Length (Minutes:Seconds) Go To Loops 
1 95 01:00  
2 95 00:30 
3 60 00:30 1 35 cycles. 
4 60 04:00   
5 12 10:00  
6 12 Pause (Holding Step) 
 
The layout of each plate was recorded allowing the well number to be cross-referenced with 
the sample and primer the well contained. After this protocol had completed the plate 
would be stored in the fridge once again in preparation for the final "clean-up" step. 
Precipitation: 
After the plate had undergone the "sequencing reaction" excess reagents and dyes needed 
to be removed from the solution so there would be greater acuity for the sequenced results.  
Using the plate from the previous reaction, 1µl of precipitation was added to each well using 
a pipette. Following this, 30µl of 100% ethanol was also added to each individual well. The 
plate was resealed and centrifuged at 4000 rpm (rotations per minute) for 30 minutes.  The 
lid was then removed and the plate was turned upside down onto tissue paper and firmly 
patted down to remove most of the 100% ethanol, it was then placed back into the 
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centrifuge and spun upside down with the lid off at 400rpm for 1 minute. The DNA would 
remain adhered to the bottom of the well in a pellet and would not be dislodged during this 
process.   
200µl of 70% ethanol was then added to each well and once again centrifuged at 4000rpm 
for 20 minutes; afterwards it would be turned upside down again and patted before being 
recentrifuged at 400rpm for another minute. These steps were to ensure the supernatant of 
ethanol and leftover reagent from previous reactions would be completely removed leaving 
only a pellet of the DNA sample in each well. Without this step the sequencing signal would 
be almost unreadable, the speed of each cycle was also very important if the speed was not 
adjusted when the lid was off the DNA pellet would also be lost. 
10µl of "Hi-Di formamide" was pipette into each well to resuspend the pellet for 
sequencing.  The plate was then run at 95°C for 5 minutes in a PCR machine to denature the 
sample. It was then stored on ice until it the plate was sequenced by a lab technician using 
an Applied Biosystems 3730 DNA analyser. 
Analysis: 
Analysis of the sequenced samples was performed using a program called "Bioedit 
(Biological Sequence alignment editor)" available at 
"http://www.mbio.ncsu.edu/bioedit/bioedit.html" (last checked 4/7/2013). The sequence 
of the samples would be compared and aligned against the known or expected sequence for 
that region, differences would be noted including homozygote/heterozygote changes. 
Statistical analysis was performed using "MedCalc" using a combination of Kaplain-Meier 
analysis and a logrank test to produce survival curves and data about age of onset on the 
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censored information. The stated threshold for statistical significance is a P-value of less 
than 0.05. 
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Results: 
BHD Modifier Study 
Analysis of the genotyping data was performed in two steps. Firstly the frequency of 
homozygotes and heterozygotes at each locus analysed was compared to population data 
and evidence of Hardy-Weinberg equilibrium was sought. Secondly the effect of individual 
SNP variants on the major phenotypical features of BHD was determined using Kaplan-
Meier analyses. 
Population data for each allele was acquired to compare the frequency of the heterozygotes 
and homozygotes at each locus. 
Table 7 Minor-Major Allele frequency population data (Source: 1000genomes.org) 
SNP MAF/MinorAllele Count Global Frequency  European Frequency 
ASIP rs1015362 T=0.381/829 T = 38% C = 62% T = 28% C = 72% 
ASIP rs4911414 
 
T=0.230/502 T = 23% G = 77% T = 31% G= 69% 
MITF rs149617956 A=0.001/2 G = 100% A = 0% G = 100% A = 0% 
11q.13 rs7105934 A =  0.21 A = 21% G = 79% A = 7% G = 93% 
MC1R rs1805007 T = 0.03 T = 3% C = 97% T = 8% C = 92% 
TYR rs1126809 A = 0.11 A = 11% G = 89% A = 25% G = 75% 
EPAS1 rs11894252 
 
C = 0.44 T = 56% C = 44% T = 39% C = 61% 
MMP1 rs1799750 "-" = 0.45 "-" = 45% C = 55% "-" = 49% C = 51% 
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Table 7 uses population data from 1000genomes.org to establish frequency of each variant 
allele within both a global population and a European population. 
Using the program "MedCalc" a Kaplan-Meier logrank analysis was performed on the data 
sets. The data included in the analysis was: age of onset of fibrofolliculomas and RCC and 
the type of tumour where applicable from hospital records ( though this data was 
incomplete). This data was then compared using the genotype of the patient and their 
alleles of interest. The survival and age of onset for each manifestation crossed with 
genotype produced a series of curves based upon this data; the three types of genotype 
(two homozygote, one heterozygote) were alternately grouped together to provide a series 
of curves. 
Polymorphisms that had been attributed to increase melanoma risk were analysed against 
the age of onset for fibrofolliculomas; similarly risk modifiers for RCC were tested against 
onset of renal tumours.  Previously ASIP rs4911414[T], rs1015362[G], MC1R rs1805007[T], 
TYR rs1126809 [G/A] and MITF rs149617956 have been associated with increased risk of 
developing melanomas.  
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ASIP rs1015362: 
Figure 1: ASIP rs1015362 survival curve for Fibrofolliculoma.  
 
Figure 1 displays the survival curve for fibrofolliculomas using a Kaplan-Meier analysis and a 
logrank statistical test, the C/C variant is considered 1 by the graph with the C/T and T/T 
variants grouped together as 2. These figures are presented with a combined sample size of 
61. Data analysis shows a statistical significance of P= 0.8753 which is above the stated 
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threshold for statistical significance, therefore there appears to be no difference between 
alleles.  
Figure 2: Survival curve C/C +C/T =1, T/T =2 
 
Table 8: Statistical analysis of Figure 2 
  Factors 
  1 2 
Sample size 55 6 











20 0.982 0.0180 - - 
22 0.945 0.0306 0.833 0.152 
24 - - - - 
25 0.889 0.0429 - - 
26 - - - - 
28 0.808 0.0548 - - 
30 0.586 0.0695 - - 
32 0.525 0.0706 - - 
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  Factors 
  1 2 
Sample size 55 6 











34 0.505 0.0707 0.625 0.213 
35 0.404 0.0695 0.208 0.184 
38 0.337 0.0679 - - 
39 0.314 0.0670 - - 
40 0.180 0.0565 - - 
45 0.103 0.0466 - - 
47 0.0769 0.0414 - - 
56 - - 0.000 0.000 
65 0.0513 0.0346 - - 
73 0.0256 0.0251 - - 
77 - - - - 
  Comparison of survival curves (Logrank test) 
Endpoint: Observed n 46.0 5.0 
Expected n 46.2 4.8 
Chi-square 0.01354   
DF 1   
Significance       P = 0.9074   
   
   
Hazard ratio 1.0511 
95% CI 0.4099 to 2.6955 
 
In figure 2 the same data of 61 patients were analysed with alternate grouping for the 
variants. Table 8 shows this data has a P-value of 0.9074 and is therefore not statistically 
significant.  
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ASIP rs4911414: 
Figure 3: Survival Curve for ASIP rs4911414 and age of onset for fibrofolliculomas. 
 
Table 9 Statistical analysis of Figure 3. 
  Factors 
  1 2 3 
Sample size 30 24 7 















20 - - 0.958 0.0408 - - 
22 - - 0.875 0.0675 0.857 0.132 
24 - - - - - - 
25 0.931 0.0471 0.831 0.0770 - - 
26 - - - - - - 
28 0.815 0.0751 0.787 0.0845 - - 
30 0.504 0.0981 0.656 0.0987 - - 
32 - - 0.525 0.104 - - 
34 0.466 0.0979 - - 0.686 0.186 
35 0.349 0.0937 0.437 0.103 0.343 0.195 
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  Factors 
  1 2 3 
Sample size 30 24 7 















38 0.249 0.0896 0.394 0.102 - - 
39 - - 0.350 0.0996 - - 
40 0.200 0.0844 0.175 0.0794 0.171 0.156 
45 0.150 0.0767 0.0583 0.0545 - - 
47 0.0998 0.0653 - - - - 
56 - - - - 0.000 0.000 
65 0.0499 0.0481 - - - - 
73 - - 0.000 0.000 - - 
77 - - - - - - 
  Comparison of survival curves (Logrank test) 
Endpoint: Observed n 23.0 22.0 6.0 
Expected n 23.1 21.7 6.3 
Chi-square 0.01697   
DF 2   
Significance       P = 0.9916   
 
The P-value quoted in Table 9 is 0.9916 which is above the threshold for statistical 
significance. 
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Figure 4 Survival Curve for ASIP rs4911414 and age of onset for fibrofolliculomas 
 
Table 10 Statistical analysis of Figure 4. 
  Factors 
  1 2 
Sample size 30 31 











20 - - 0.968 0.0317 
22 - - 0.871 0.0602 
24 - - - - 
25 0.931 0.0471 0.836 0.0671 
26 - - - - 
28 0.815 0.0751 0.801 0.0728 
30 0.504 0.0981 0.697 0.0847 
32 - - 0.592 0.0910 
34 0.466 0.0979 0.557 0.0921 
35 0.349 0.0937 0.418 0.0917 
38 0.249 0.0896 0.383 0.0904 
39 - - 0.348 0.0887 
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  Factors 
  1 2 
Sample size 30 31 











40 0.200 0.0844 0.174 0.0707 
45 0.150 0.0767 0.0871 0.0561 
47 0.0998 0.0653 - - 
56 - - 0.0435 0.0417 
65 0.0499 0.0481 - - 
73 - - 0.000 0.000 
77 - - - - 
  Comparison of survival curves (Logrank test) 
Endpoint: Observed n 23.0 28.0 
Expected n 23.1 27.9 
Chi-square 0.0007081   
DF 1   
Significance       P = 0.9788   
   
   
Hazard ratio 1.0068 
95% CI 0.5801 to 1.7475 
 
Table 10 shows a statistically insignificant P-value of 0.9788 suggesting these results lack the 
statistical power to confirm the hypothesis. 
MITF rs149617956 (E318K) 
MITF rs149617956 (E318K) was analysed in the 57 patient samples, every sample produced 
a G/G homozygote with no variation. The A allele has a very low frequency in a given 
population, (Yokoyama, et al., 2011) reported a frequency of 0.009 in case samples and a 
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frequency of 0.004 in the control samples so this is to be expected (Chatzinasiou, et al., 
2011). 
11q.13.3 loci (rs7105934) 
Figure 5 Survival Curve for 11q13.3 loci (rs7105934) and age of onset for fibrofolliculomas 
 
There were no A/A genotypes present in the patient data so that cannot be compared for 
analysis. 
Table 11 Statistical analysis of Figure 5 
  Factors 
  1 2 
Sample size 56 5 











20 0.982 0.0177 - - 
22 0.929 0.0344 - - 
24 - - - - 
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  Factors 
  1 2 
Sample size 56 5 











25 0.872 0.0453 - - 
26 - - - - 
28 0.791 0.0564 - - 
30 0.649 0.0671 0.200 0.179 
32 0.588 0.0694 - - 
34 0.547 0.0703 - - 
35 0.405 0.0696 - - 
38 0.338 0.0680 - - 
39 0.315 0.0671 - - 
40 0.180 0.0567 - - 
45 0.129 0.0508 0.000 0.000 
47 0.103 0.0467 - - 
56 0.0772 0.0415 - - 
65 0.0515 0.0348 - - 
73 0.0257 0.0252 - - 
77 - - - - 
  Comparison of survival curves (Logrank test) 
Endpoint: Observed n 46.0 5.0 
Expected n 47.3 3.7 
Chi-square 0.6372   
DF 1   
Significance       P = 0.4247   
 
The P-value significance quoted in Table 11 is 0.4247 which is above the threshold for 
statistical significance suggesting these findings are non-significant.  
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Figure 6 Survival Curve for 11q13.3 loci (rs7105934) and age of onset Renal Cell Carcinoma. 
 
Figure 6: Though there appears to be an earlier age at onset in G/A heterozygotes this did 
not reach statistical significance and there are insufficient G/A heterozygotes (n=6) to make 
a reliable interpretation of the results.  
 
Table 12 Statistical analysis of Figure 6 
  Factors 
  1 2 
Sample size 58 6 











20 - - - - 
22 - - - - 
24 - - - - 
25 0.981 0.0190 - - 
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  Factors 
  1 2 
Sample size 58 6 











26 - - - - 
28 0.959 0.0285 - - 
30 - - - - 
32 - - - - 
34 - - - - 
35 0.928 0.0411 - - 
38 - - - - 
39 - - - - 
40 - - - - 
44 - - 0.500 0.354 
45 - - - - 
47 - - - - 
54 0.812 0.114 - - 
56 0.696 0.145 - - 
62 0.580 0.161 - - 
65 0.348 0.160 - - 
67 0.232 0.142 - - 
73 - - - - 
79 0.000 0.000 - - 
  Comparison of survival curves (Logrank test) 
Endpoint: Observed n 10.0 1.0 
Expected n 10.6 0.4 
Chi-square 0.8808   
DF 1   
Significance       P = 0.3480   
   
Hazard ratio 2.4909 
95% CI 0.1159 to 53.5441 
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Table 12 suggests statistical non-significance for these findings with a P value of 0.3480 
which is above the 0.05 threshold for statistical significance.  
TYR rs1126809 (R402Q) 
Figure 7 Survival Curve for TYR rs1126809 (R402Q) and age of onset for Fibofolliculomas 
 
Figure 7 appears to show the G/G homozygote genotype being the most deleterious with an 
earlier age of onset for Fibrofolliculomas in comparison to G/A and A/A. Previous studies 
have suggested the A allele modifies risk and increases the risk of both FFs and cutaneous 
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Table 13 Statistical analysis of Figure 7 
  Factors 
  1 2 
Sample size 28 33 











20 0.964 0.0351 - - 
22 0.893 0.0585 0.970 0.0298 
24 - - - - 
25 0.781 0.0790 - - 
26 - - - - 
28 0.632 0.0926 - - 
30 0.409 0.0947 0.790 0.0765 
32 - - 0.682 0.0878 
34 - - 0.611 0.0921 
35 0.223 0.0803 0.539 0.0942 
38 - - 0.423 0.0947 
39 - - 0.385 0.0936 
40 0.0446 0.0430 0.308 0.0893 
45 0.000 0.000 0.220 0.0827 
47 - - 0.176 0.0769 
56 - - 0.132 0.0691 
65 - - 0.0880 0.0584 
73 - - 0.0440 0.0427 
77 - - - - 
  Comparison of survival curves (Logrank test) 
Endpoint: Observed n 26.0 25.0 
Expected n 17.1 33.9 
Chi-square 8.9989   
DF 1   
Significance       P = 0.0027   
   
Hazard ratio 0.4851 
95% CI 0.2713 to 0.8676 
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The P-value is 0.0027 which suggests a statistically significant result, that the G/G genotype 
is the most deleterious contrary to previous findings where the A allele has a greater 
association in sporadic patients with basal cell carcinoma (Gudbjartsson, et al., 2008). 
Figure 8 Survival Curve for TYR rs1126809 (R402Q) and age of onset for Fibofolliculomas 
 
Figure 8 clearly illustrates the G/G genotype being the most deleterious with the A/A 
genotype (though there were only three patients in this group) being associated with later 
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Table 14 Statistical analysis of Figure 8. 
  Factors 
  1 2 3 
Sample size 28 30 3 















20 0.964 0.0351 - - - - 
22 0.893 0.0585 0.967 0.0328 - - 
24 - - - - - - 
25 0.781 0.0790 - - - - 
26 - - - - - - 
28 0.632 0.0926 - - - - 
30 0.409 0.0947 0.773 0.0817 - - 
32 - - 0.657 0.0929 - - 
34 - - 0.580 0.0967 - - 
35 0.223 0.0803 0.503 0.0981 - - 
38 - - 0.419 0.0980 0.500 0.354 
39 - - 0.377 0.0967 - - 
40 0.0446 0.0430 0.293 0.0916 - - 
45 0.000 0.000 0.195 0.0831 - - 
47 - - 0.147 0.0754 - - 
56 - - 0.0977 0.0642 - - 
65 - - - - 0.000 0.000 
73 - - 0.0489 0.0472 - - 
77 - - - - - - 
  Comparison of survival curves (Logrank test) 
Endpoint: Observed n 26.0 23.0 2.0 
Expected n 17.1 30.2 3.7 
Chi-square 7.1336   
DF 2   
Significance       P = 0.0282   
 
These contradictory findings also present with a statistically significant P-value of 0.0282.  
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Figure 9 TYR rs1126809 and RCC risk 
 
Table 15 Statistical Analysis of Figure 9 
  Factors 
  1 2 
Sample size 29 35 











20 - - - - 
22 - - - - 
24 - - - - 
25 0.962 0.0377 - - 
26 - - - - 
28 - - 0.966 0.0339 
30 - - - - 
32 - - - - 
34 - - - - 
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  Factors 
  1 2 
Sample size 29 35 











35 - - 0.912 0.0612 
38 - - - - 
39 - - - - 
40 - - - - 
44 - - 0.811 0.110 
45 - - - - 
47 - - - - 
54 - - 0.648 0.170 
56 0.641 0.263 - - 
62 - - 0.486 0.189 
65 0.000 0.000 - - 
67 - - 0.324 0.183 
73 - - - - 
79 - - 0.000 0.000 
  Comparison of survival curves (Logrank test) 
Endpoint: Observed n 4.0 7.0 
Expected n 3.6 7.4 
Chi-square 0.06803   
DF 1   
Significance       P = 0.7942   
 
There appears to be no statistically significant difference between alleles in terms of RCC 
risk given the P value quoted in table 10 (P = 0.7942). 
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EPAS1 rs11894252 
Figure 10 Survival Curve for EPAS1 rs11894252 and age of onset for RCC. 
 
Figure 10 displays the T/T homozygote with the earliest age of onset before age 70, the C/C 
genotype appears to be the next most deleterious with the C/T genotype having the latest 
age of onset. 
Table 16 Statistical analysis of Figure 9 
  Factors 
  1 2 3 
Sample size 21 38 5 















20 - - - - - - 
22 - - - - - - 
24 - - - - - - 
25 - - 0.971 0.0290 - - 
26 - - - - - - 
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  Factors 
  1 2 3 
Sample size 21 38 5 















28 - - 0.939 0.0417 - - 
30 - - - - - - 
32 - - - - - - 
34 - - - - - - 
35 0.923 0.0739 - - - - 
38 - - - - - - 
39 - - - - - - 
40 - - - - - - 
44 - - 0.783 0.147 - - 
45 - - - - - - 
47 - - - - - - 
54 0.738 0.175 - - - - 
56 0.554 0.207 - - - - 
62 0.369 0.204 - - - - 
65 0.185 0.166 0.391 0.286 - - 
67 - - - - 0.000 0.000 
73 - - - - - - 
79 0.000 0.000 - - - - 
  Comparison of survival curves (Logrank test) 
Endpoint: Observed n 6.0 4.0 1.0 
Expected n 5.4 4.1 1.5 
Chi-square 0.2282   
DF 2   
Significance       P = 0.8922   
 
The P-value from Table 16 for Figure 10 is 0.8922 which suggests statistical non-significance; 
this would explain the unusual finding of both homozygotes being more deleterious than 
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the heterozygote. If one allele was noted for having a harmful effect you might expect the 
heterozygote with the same allele to be more damaging than the homozygote without.  
Figure 11 Survival Curve for EPAS1 rs11894252 and age of onset for RCC. 
 
Figure 11 describes a similar trend depicted in Figure 10, with the T/T homozygote being 
associated with the earliest age of onset. The grouped C/C and C/T genotypes show a later 
age of onset. 
Table 17 Statistical analysis of Figure 11 
  Factors 
  1 2 
Sample size 58 6 











20 - - - - 
22 - - - - 
24 - - - - 
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  Factors 
  1 2 
Sample size 58 6 











25 0.981 0.0190 - - 
26 - - - - 
28 0.960 0.0275 - - 
30 - - - - 
32 - - - - 
34 - - - - 
35 0.928 0.0412 - - 
38 - - - - 
39 - - - - 
40 - - - - 
44 0.857 0.0784 - - 
45 - - - - 
47 - - - - 
54 0.734 0.132 - - 
56 0.612 0.157 - - 
62 0.490 0.166 - - 
65 0.245 0.148 - - 
67 - - 0.000 0.000 
73 - - - - 
79 0.000 0.000 - - 
  Comparison of survival curves (Logrank test) 
Endpoint: Observed n 10.0 1.0 
Expected n 9.5 1.5 
Chi-square 0.2146   
DF 1   
Significance       P = 0.6432   
 
Table 17 shows a P-value of 0.6432 - these results are not considered statistically significant. 
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MMP1 rs1799750 (G/G) 
The polymorphic variation at MMP1 is either a G allele or a deletion. 
Figure 12 Survival Curve for MMP1 rs1799750 and age of onset for RCC. 
 
The survival curve in Figure 12 shows the G/G and G/- genotypes to be the least deleterious 
with the latest age of onset, the homozygous deletion (2) results in an age of onset for RCC 
at age 60. 
Table 18 Statistical analysis of Figure 12 
  Factors 
  1 2 
Sample size 50 13 











20 - - - - 
22 - - - - 
24 - - - - 
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  Factors 
  1 2 
Sample size 50 13 











25 0.979 0.0210 - - 
26 - - - - 
28 - - 0.889 0.105 
30 - - - - 
32 - - - - 
34 - - - - 
35 0.942 0.0409 - - 
38 - - - - 
39 - - - - 
40 - - - - 
44 0.838 0.105 - - 
45 - - - - 
47 - - - - 
54 0.718 0.143 - - 
56 0.598 0.162 - - 
62 - - 0.000 0.000 
65 0.359 0.163 - - 
67 0.239 0.146 - - 
73 - - - - 
79 0.000 0.000 - - 
  Comparison of survival curves (Logrank test) 
Endpoint: Observed n 9.0 2.0 
Expected n 9.7 1.3 
Chi-square 0.5523   
DF 1   
Significance       P = 0.4574   
 
These results do not appear to have statistical significance based on the P-value in Table 18 
which is quoted at 0.4574 above the P = >0.05 threshold. 
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Figure 13 Survival Curve for MMP1 rs1799750 and age of onset for RCC. 
 
Figure 13:These results appear to be statistically insignificant given the P-value quoted in 
Table 19.  
 
Table 19 Statistical analysis of Figure 13 
  Factors 
  1 2 
Sample size 12 51 











20 - - - - 
22 - - - - 
24 - - - - 
25 - - 0.979 0.0206 
26 - - - - 
28 - - 0.956 0.0306 
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  Factors 
  1 2 
Sample size 12 51 











30 - - - - 
32 - - - - 
34 - - - - 
35 - - 0.919 0.0465 
38 - - - - 
39 - - - - 
40 - - - - 
44 0.667 0.272 - - 
45 - - - - 
47 - - - - 
54 - - 0.788 0.128 
56 - - 0.656 0.160 
62 - - 0.525 0.174 
65 0.000 0.000 0.394 0.173 
67 - - 0.263 0.157 
73 - - - - 
79 - - 0.000 0.000 
  Comparison of survival curves (Logrank test) 
Endpoint: Observed n 2.0 9.0 
Expected n 1.6 9.4 
Chi-square 0.1526   
DF 1   
Significance       P = 0.6961   
   
   
Hazard ratio 0.7496 
95% CI 0.1384 to 4.0589 
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The P-value seen in Table 19 (0.6961) is above the threshold for statistical significance 
therefore these results are unlikely to be statistically significant.  




 Table 20 Statistical analysis of Figure 13 
  Factors 
  1 2 
Sample size 48 12 











20 0.979 0.0206 - - 
22 0.958 0.0288 0.833 0.108 
24 - - - - 
25 0.915 0.0408 0.741 0.129 
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  Factors 
  1 2 
Sample size 48 12 











26 - - - - 
28 0.821 0.0576 - - 
30 0.610 0.0742 0.556 0.149 
32 0.539 0.0760 - - 
34 0.516 0.0762 0.463 0.150 
35 0.352 0.0730 - - 
38 0.298 0.0711 0.370 0.146 
39 0.271 0.0696 - - 
40 0.108 0.0503 - - 
45 - - 0.123 0.112 
47 - - 0.000 0.000 
56 0.0812 0.0444 - - 
65 0.0541 0.0370 - - 
73 0.0271 0.0266 - - 
77 - - - - 
  Comparison of survival curves (Logrank test) 
Endpoint: Observed n 40.0 10.0 
Expected n 39.8 10.2 
Chi-square 0.005666   
DF 1   
Significance       P = 0.9400   
 
These findings appear to be statistically insignificant given the P-value (0.94) quoted in Table 
20. 
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Figure 15 Survival Curve for MMP1 rs1799750 and age of onset for FF. 
 
 
Table 21 Statistical analysis of Figure 14 
  Factors 
  1 2 3 
Sample size 10 38 12 















20 0.900 0.0949 - - - - 
22 - - 0.974 0.0260 0.833 0.108 
24 - - - - - - 
25 - - 0.921 0.0437 0.741 0.129 
26 - - - - - - 
28 0.750 0.158 0.837 0.0609 - - 
30 0.450 0.190 0.642 0.0797 0.556 0.149 
32 - - 0.558 0.0827 - - 
34 - - 0.530 0.0831 0.463 0.150 
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  Factors 
  1 2 3 
Sample size 10 38 12 















35 0.300 0.176 0.363 0.0802 - - 
38 - - 0.302 0.0774 0.370 0.146 
39 - - 0.272 0.0753 - - 
40 0.000 0.000 0.121 0.0562 - - 
45 - - - - 0.123 0.112 
47 - - - - 0.000 0.000 
56 - - 0.0907 0.0496 - - 
65 - - 0.0605 0.0413 - - 
73 - - 0.0302 0.0297 - - 
77 - - - - - - 
  Comparison of survival curves (Logrank test) 
Endpoint: Observed n 6.0 34.0 10.0 
Expected n 4.7 35.1 10.2 
Chi-square 0.3724   
DF 2   
Significance       P = 0.8301   
 
Given the P-value seen in Table 21 it appears these results do not represent a statistically 
significant finding. 
MC1R rs1805007 [T] and ASIP rs1015362[G] 
Whilst these variants were screened within the patient samples, it was later revealed (due 
to inconsistencies in information on the target sequences) that the primers designed bound 
to a different region. Therefore these results do not represent the intended polymorphisms 
and are not included for analysis or discussion. 
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Analysis of Exome Sequencing in a renal tumour from a BHD patient 
Blood and renal tumour DNA from a BHD patient with a history of two gastrointestinal tract 
tumours was analysed using exome sequencing. Although additional clinical data was not 
available, the tumour exome results were analysed to identify candidate loss of function 
mutations in candidate human cancer genes. Potentially interesting mutations were 
selected and prioritised based upon mutation type and relevance to BHD and renal cancer. 
The criteria used from high to low were: 
Somatic Nonsense mutation, Somatic Frameshift mutation, Splice site mutation predicted to 
affect splicing, missense substitution predicted to be pathogenic and linked to cancer, 
somatic substitution predicted to be pathogenic but not linked to cancer and finally benign 
substitution predicted to be non-pathogenic and not linked to cancer. Using these criteria 
the mutations most likely to be deleterious and associated with a significant increase to 
cancer vulnerability were selected. 
After this these mutations and genes were run through COSMIC software alongside manual 
selection to determine their relevance to cancer, in particular relevance to kidney cancers 
such as VHL or FLCN. I then undertook mutation analysis of the selected variations in 
sporadic RCC to help determine if the gene of interest was likely to be a frequent target of 
somatic mutation in renal tumourigenesis. Ultimately this approach might identify genes 
implicated in BHD and sporadic renal tumourigenesis, and germline variants that affected 
the function of such genes could then be investigated as candidate modifier alleles for RCC 
risk in BHD patients. 
Page | 75 
 
FLCN: 
Within the exome data, the first patient presented a c.G907A:p.G303R non-synonymous 
mutation (NM_144606) in FLCN on exon 8. This germline mutation did not appear on the 
FLCN mutation database and appeared to be novel (Leiden University Medical Center, 
2009).  
The second tumour that underwent exome analysis came from a Japanese patient who 
presented with a homozygous/hemizygous splicing variation on exon 10 - c.1062+6C>T on 
FLCN and two separate intronic changes. This splice-site mutation has previously been 
categorised as a SNP (rs8065832) in a study attempting to find a link between Folliculin 
mutations and severe COPD (Chronic obstructive pulmonary disease however, no significant 
association was found between them (Choo, et al., 2008). 
TP53: 
This gene is the most commonly mutated tumour suppressor gene in human cancer. 
Analysis of the tumour exome data revealed an exon 4 mutation c.C215G:pP72R. This 
mutation has previously been reported to be pathogenic. Variants at this location including 
c.G215C:pR72P have a demonstrated association with survival rates in advanced ovarian 
cancer syndromes causing functional changes (Wang, et al., 2004) and differences in 
apoptotic potential (Dumont, et al., 2003). Though TP53 mutations are reported in kidney 
cancer, inspection of the exome sequencing results for blood DNA revealed that the TP53 
mutation was also present in blood and was not a somatic mutation. 
The British patient presented with multiple mutations within TP53 as described below: 
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Table 22 TP53 variants detected 
Exon Type Status 
Exon 5 c.T526C:p.C176R Novel 
Exon 1 c.T130C:p.C44R Novel 
Exon 4 c.C215G:pP72R Confirmed Pathogenic 
 
The tumour from the Japanese patient also presented with the c.C215G:p72R variant on 
TP53. This change is well documented and has been associated with multiple cancer 
syndromes and is categorised as the Rs1042522 variant (Johnson, et al., 2007). 
ARHGEF5 
The first potential modifier gene selected was ARHGEF5 located on 7q35 also known as Rho 
guanine nucleotide exchange factor which produces a protein of the same name.  This 
oncogene is responsible for producing proteins stimulated by Rho-factors which have critical 
roles in extracellular communication and signalling and are involved in organisation of the 
cytoskeleton; both of these attributes are found dysregulated within cancerous growths and 
contribute to progression and metastasis (Debily, et al., 2004). Evidence suggests ARHGEF5 
uses RhoA factors to regulate dendritic cell migration, and has been shown to significantly 
alter expression of RhoA and RhoB in kidney cells; RhoC and G are less affected by this 
(Wang, et al., 2009). ARHGEF5 has been implicated in breast cancer, and it is currently 
known that Folliculin interacts and regulates with Rhoa-A and rho-guanine factors leading to 
altered RhoA signalling and cell adhesion (Nahorski, et al., 2012) (Medvetz, et al., 2012). The 
patient in our exome study had a heterozygous "stopgain" or nonsense mutation on exon 2 
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with no other novel changes. The Japanese patient’s tumour presented with three intronic 
variations on ARHGEF5 but no exonic variations. 
Znf180 
ZNF180 encodes Zinc Finger Protein 180 and is 5 exons long, Zinc fingers are involved in 
up/down regulation and gene expression, abnormalities typically result in a deficiency in 
DNA repair mechanisms which can naturally lead towards malignancies (Wang, et al., 1996). 
The patient presented with a novel heterozygous frameshift mutation on exon 5 
(c.471delT:p.D157fs).  
IGFBP2 
Insulin-Like Growth Factor Binding protein 2 (IGFBP2) is produced by the gene of the same 
name located on chromosome 2q35; it contains 4 exons and 3 introns. These growth factors 
modulate growth and development through inhibition or stimulation using IGF receptors, 
and have been linked to breast cancers through endothelial recruitment and signalling (Png, 
et al., 2011). There is already a precedent for IGFBP2 over-expression to result in increased 
resistance to chemotherapy and its role as a survival factor in breast cancer cell proliferation 
(Foulstone, et al., 2013). IGFBP2 factors are implicated in renal diseases through over-
expression of these growth factors (Wolf, et al., 2000). Levels of IGFBP2 expression are 
found to be increased in patients with active prostate carcinoma (Jean Ho & Baxter, 1997).  
A recent study determined the IGFBP2 to be a predictor of renal function deterioration in 
type II diabetes where an increase in IGFBP2 expression resulted in a greater mortality and 
faster decline in kidney function (Narayanan, et al., 2012).  The patient presented with a 
novel heterozygous non-frameshift insertion of "CGC" at position 64-65. 
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FOXC1 
The FOXC1 or "Forkhead Box C1" gene is located a chromosome 6p25; this gene family is 
named after the "fork-headed" DNA-binding domain and their role as transcription factors. 
As a result FOX regulates gene expression and is associated with developmental roles during 
embryogenesis; their regulation affects proliferation and differentiation of cells and cell 
growth making them potential targets for mutation during carcinogenesis. Over-expression 
of the FOXC1  proteins result in reduced patient survival in lung cancer (Wei, et al., 2013) 
and pancreatic ductal adenocarcinoma (Wang, et al., 2013), hepatocellular carcinoma (HCC) 
through tumour metastasis (Xia, et al., 2013) and microvascular invasion in HCC (Xu, et al., 
2012). FOXC1 is necessary for the formation of the kidney and urinary tract (Kume, et al., 
2000) with mutations in FOXC1 resulting in congenital abnormalities in human kidneys 
(Nakano, et al., 2003).  The severe patient presented with a novel heterozygous non-
frameshift insertion of GCG at position 1141-1142. The Japanese tumour sample presented 
with a nonframeshift insertion of three bases (c.1361_1362insCGG:p.G454delinsGG).  
Of the four genes selected as potential genes mutated in sporadic RCC, ZNF180, IGFBP2 and 
FOXC1 were unable to be fully screened due to time constraints. The ARHGEF5 gene was 
fully completed and showed multiple novel variations listed below: 
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 Analysis of candidate genes in sporadic renal tumours: 
Sequencing analysis of ARHGEF5 in tumour DNA presented several novel sequence 
variations not found within current literature. These results were obtained from a sample 
size of 37 patients with sporadic RCC.  
Table 23 ARHGEF5 novel variations. 
Variant Location Exon Polyphen/Sift 
Stopgain C.29insGCTGA p.Ala29GlySer30* 2 Truncating 
Synonymous   c.1283C>T (p(=)) 2 Benign  
Synonymous   c.1368C>A (P(=)) 2 Benign 
Non-Synonymous c.1845G>C p.Gln615Hist 2 Damaging 
Stop Codon c.2870C>G p.S957* 2 Truncating 













Any novel variations detected were analysed using Polyphen and Sift software with the aim 
to predict any functional effects these variations might cause. The majority of these variants 
appeared to be benign with a small number of them predicted to be damaging. 
Two clear truncating mutations were detected in tumour DNA. A nonsense mutation at 
codon 29 in exon 2 was detected in the exome data from the tumour DNA of the BHD 
patient and confirmed by Sanger sequencing. In addition a second c.2870C>G p.S957* 
mutation at codon 957 was detected in one of the 37 sporadic RCC tested. Neither of these 
changes were detected in the matched "normal" (non-tumour) DNA samples for both these 
patients and so this was consistent with a somatic mutation. 
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The non-synonymous substitution of glutamine (GLN) to glutamic acid (GLU) was detected 
in another patient but was not found within their normal DNA sample suggesting a somatic 
change. Polyphen/SIFT predict this variation to be benign. 
The predicted damaging mutations were also confirmed to be somatic changes in the 
patients that presented with them; none of the damaging mutations were shared between 
patients. With the exception of the truncating variant, which we originally detected in the 
tumour from the British patient with BHD syndrome.  Out of the 37 patients screened only 3 
novel damaging variants were detected in three separate cases.   
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Discussion: 
With the aim of identifying possible alleles that might modify or predispose a BHD patient 
with a Folliculin mutation towards a specific phenotype such as melanoma or renal cell 
carcinomas; sequencing and statistical analysis was performed on approximately 70 BHD 
patients.  
Of the polymorphisms analysed; only MITF showed a lack of any variation within the 72 
samples with every patient displaying a G/G genotype.  This was not unexpected given the 
noted low frequency of the deleterious A allele within a population (Yokoyama, et al., 2011) 
and the relatively small sample size used in this study. Yokoyama reported the MITF 
polymorphism with a frequency of 0.0085 in controls and 0.0176 within patients with a 
melanoma within a UK population with only 52 patients with the variant and 3992 without. 
The Australian sample group showed a similar ratio but with a lower frequency of the allele 
than the UK. With the Australian and UK frequencies combined the overall frequency for the 
allele was 0.0171 in affected cases and 0.0079 in control groups. Given these circumstances 
the lack of any variation is less surprising; it may still be a potential modifier for melanoma 
within BHD but this study simply lacked enough samples to for such a low frequency variant 
to be present within the patient samples. A more in-depth study with a wider sample size 
may reveal a possible predisposition to the associated skin phenotypes to BHD. Had there 
been variation within this polymorphism especially with such a small sample size it might 
suggest a strong link between a deleterious MITF variant and fibrofolliculoma risk. 
Within the literature the T allele of ASIP rs4911414 has been shown to associate with a 
higher risk of melanoma (Kanetsky, et al., 2002). Analysis of the ASIP rs4911414 variant 
shows statistically insignificant results in association with fibrofolliculoma risks with P-values 
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of greater than 0.05 (P =0.9916 and P =0.9788) these figures are far outside a significance 
threshold and cannot be relied upon.  
The 11q13.3 locus variant rs7105934 only presented with the G/G and G/A haplotypes 
within this study, there were no homozygote A/As. The A allele has been associated in 
previous studies with a protective effect against renal cell carcinoma with an OR of 0.69, 
however evidence suggests environmental and lifestyle factors can result in the loss of this 
protective effect. Factors such as smoking, obesity and heavy drinking have been implicated 
(Purdue, et al., 2011). Given the statistical insignificance of the findings (P = 0.4247 and 
0.3480) presented it is less likely that this polymorphism modifies RCC risk. 
When compared with age of onset for fibrofolliculomas, TYR rs1126809 (R402Q) the G/G 
haplotypes in both Figure 7 and 8 are associated with the earliest age of onset. In figure 8 
the A/A homozygote results in a later onset than G/G but earlier than G/A. In this study only 
three patients presented with an A/A homozygote out of 67 samples with G/G having 28 
patients and G/A 30. This might partially explain the abnormal curve for the A/A in 
comparison with the other two haplotypes, though it does not account for why the G/G 
haplotype has the earliest age of onset. In the genome-wide association study of 
approximately 4000 patients diagnosed with basal cell carcinomas or cutaneous melanomas 
by (Gudbjartsson, et al., 2008) the R402Q variant was shown to increase the risk of 
cutaneous melanoma with an odds ratio of 1.21 alongside basal cell carcinomas with an 
odds ratio of 1.14. These findings suggest both A/A and G/A genotypes confer increased risk 
and contrast with the findings of the prior studies. Nevertheless the findings in my patient 
group were statistically significant. There are several explanations for this discrepancy. 
Firstly the mechanisms of tumourigenesis in fibrofolliculomas in BHD patients may differ 
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from those in sporadic melanoma and an allele protective for melanoma might predispose 
to fibrofolliculomas. The tumourigenesis processes in fibrofolliculomas may differ from 
those in melanoma and basal cell carcinoma such that different modifier genes are 
implicated (though ultra violet radiation exposure is a risk factor for both melanoma and 
basal cell carcinoma it has not been implicated in fibrofolliculomas). Little is known about 
tumourigenic processes in fibrofolliculomas in BHD syndrome and how these compare to 
melanoma and so it is not possible to refute or confirm this hypothesis. A second possibility 
is the small sample size (<70) in my study resulted in a false positive finding. Although the 
effect of the TYR SNP appeared statistically significant, this was without correcting for 
multiple testing and application of Bonferroni correction which might have revealed this 
result to be a false positive. Nevertheless this finding does suggest that the SNP should be 
analysed in a larger group of patients. 
EPAS rs11894252 was tested against age of onset for renal cell carcinoma. Findings show 
statistically insignificant P-values of 0.8922 and 0.6432 suggesting these findings are not 
associated with RCC risk. 
For the MMP1 rs1799750 polymorphism G/G variant in the literature is associated with an 
increased risk of several cancers (Ricketts, et al., 2009). However, this study lacks the 
statistical power to support these findings completely given the P values in Table 17 and 18 
(P = 0.6961 and 0.94 respectively). Within the patient samples, the majority of the patients 
developed fibrofolliculomas with very few developing RCC it could be argued this 
polymorphism may also increases the likelihood of developing FFs however statistical 
evidence does not support this hypothesis given the insignificant P-value of 0.8301 seen in 
Table 19 suggesting there is no correlation.  
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ARHGEF5: 
In terms of the exome project, the stop-codon insertion at the start of exon 2 on ARHGEF5 
showed promise, appearing both in the BHD patient with the severe phenotype and a 
somatic p53 mutation and one of our sporadic RCC patients. This variation appeared in 
neither patient's normal DNA samples and only appeared within tumour derived DNA 
samples. The addition of a stop-codon results in truncation of the transcript for exon 2 and 
results in a non-functional protein which would most likely have an effect on the phenotype. 
Given the role of ARHGEF5 in cell structure organisation and extracellular 
communication/RhoA signalling in Kidney cells, this gene represents a likely target for a 
modifier of renal carcinoma risk within a BHD patient. However, out of the 37 patients only 
one other patient presented with this somatic change. It is difficult to determine whether 
this variation would be a driving factor within renal cancer or whether it might represent a 
“passenger mutation” (Muller, et al., 2012). The gene is associated with aggressive 
tumourigenesis and metastasis within breast cancers (Debily, et al., 2004) and may also 
provide a similar role in renal cell carcinomas. This particular variation was currently 
unreported in literature or websites documenting variation so this change is reasoned to be 
a novel variant. The two other variations predicted to be damaging were present 
individually in two separate patients’ tumour DNA samples both variants are non-
synonymous changes resulting in a different amino acid being produced by the transcript. 
These changes were not found in any tumours or current literature, Polyphen/Sift software 
predicts them as damaging/possibly damaging. The c.2870C>G p.S957* stopgain mutation 
has been documented on COSMIC (COSM1488330) and has previously been found within a 
breast cancer sample (Wellcome Sanger Trust Institute, 2013). Further investigation would 
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be required to determine the effects and implications of these possible mutations in 
tumourigenesis including a larger sample size of patients.  
Finally several synonymous or "silent" novel variants within the ARHGEF5 gene were found 
within patient tumour DNA. These variants are a change in the sequence but given the 
redundancy of the base combinations used in producing specific amino acids these variants 
do not change the amino acid or the final protein product. Polyphen/SIFT software describes 
them as benign and unlikely to have any effect on phenotype as they do not impair or 
modify protein production. However it is worth noting that variants which are classified as 
silent may affect splicing sites for other proteins produced by the same transcript.  
Ultimately though synonymous changes are a low priority and any variations or mutations 
that might modify the risk or progression of tumourigenesis are likely to be non-
synonymous or stopgain mutations. 
  
Page | 86 
 
Study Limitations: 
Limitations of analysing SNPs as modifiers of BHD phenotype risk: 
Given the nature of a rare disease such as BHD, this particular study suffers from a small 
sample size of patients making it difficult to draw any decisive conclusions towards 
modifying risk of a specific phenotype. Without germline DNA from very large numbers of 
BHD patients and with incomplete clinical data it would be difficult to detect subtle 
modifying effects that a common polymorphic variant might exert. One of the main 
arguments behind SNP polymorphisms driving a specific phenotype is that they might 
modify a particular outcome by a very small percentage; often they work in tandem with 
other SNPs and modify risk more than they would individually. Naturally this makes 
detecting the effect of a SNP alone very difficult without significant sample sizes such as a 
genome-wide association study (GWAS). GWAS often have sample sizes within the 
thousands and often across different populations should there be a noticeable difference in 
allele frequency within a given population. Given our small sample size the lack of a positive 
finding does not necessarily indicate that a SNP does not modify a particular outcome in 
BHD merely that we lack the numbers and statistical power to prove that it does.  
The strength of a Kaplan-Meier analysis is its effectiveness in processing censored patient 
data and allows for the inclusion of incomplete data for example if a patient has withdrawn 
from a study or their symptoms are no longer reported. The logrank test was an appropriate 
nonparametric (lack of parameters or structure assumptions within the data) statistical 
study to analyse data generated by a Kaplain-Meier curve given its tolerance for right-
censored data. These tests allowed for a greater statistical significance to be gleaned from 
the data, however with one exception (TYR) these tests were not enough. The majority of 
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results were statistically non-significant and we must accept the null hypothesis. It’s 
important to avoid over-interpreting a single statistically significant result within a series of 
statistically insignificant results; it is possible a result like this might occur through random 
chance alone (Bland & Altman, 1995). Bonferroni correction is a conservative method which 
aims to prevent occurrences of this arising from multiple tests within the same subset of 
data. This method can be used to avoid Type I statistical errors (rejecting a null hypothesis 
based on a false positive result) it is less effective and may increase the risk of a Type II error 
(when an incorrect null hypothesis is not rejected) (Genomics and Bioinformatics Group, 
2013). 
Another potential flaw within the study especially given the recurring problems of a limited 
sample size is the presence of family members or large families within the data. Related 
patients might skew data towards a certain outcome, as they would likely share similar 
polymorphisms and inherited genotypes causing a greater representation of a particular 
genotype than you might expect from a random population. Whilst the data included a 
family of five people, since censored data does not take this factor into account it might 
exacerbate issues with false positives.  The SNP in TYR was statistically significant (without 
correction for multiple testing), however this study found opposite and contradictory 
findings to previous literature so this result may be a false finding. 
Ultimately a larger study would be required to detect subtle effects that may be caused by 
the suggested SNPs; it may also be informative to use multiple different populations within 
the study. Several SNPS are noted to vary in frequency such as the MC1R polymorphisms 
and any effects they might have would be lost in a study using an inappropriate population 
set. EPAS1 rs11894252 is an excellent example of this variation as the minor allele within a 
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global population is reversed in a European population becoming the most common variant 
as seen in Table 7. In summary, the work reported here can provide the basis for a larger 
follow up study. Though I have been cautious interpreting the importance and validity of my 
positive finding it would be important to follow up the finding and confirm or refute its 
significance. 
Limitations of analysing candidate genes in sporadic renal tumours: 
A major limitation of this study was the available time, as a result several promising 
candidate genes were selected with primers designed and tested but given time constraints 
were unable to be sequenced in all of the tumours. The short amount of time available was 
exacerbated by difficulty producing reliable primers for each region as they had to be 
designed manually as well as availability of PCR machines and the sequencer.  These 
problems were compounded by mechanical failures resulting in the need to replace or 
repair these machines in order to progress and generate additional data. Whilst these 
problems are out of the scope of the study's design they were a contributing factor towards 
the amount of data produced. Given the size of ARHGEF5 testing all 15 exons within 37 
patients took a fair amount of time to accomplish. 
Whilst the limitations of the use of exome sequencing described previously have been 
raised it is still important to confirm information used from it to avoid false positive results. 
This study tested the severe patient's normal and tumour DNAs for mutations in the 
candidate genes that were selected to confirm their presence before analysing other patient 
DNA samples. This was an effort to avoid searching for variations that weren't there based 
off misinformation generated by large-scale testing.  
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It was interesting that a TP53 mutation detected by exome sequencing in the tumour DNA 
from a BHD patient was present in the germline and was not a somatic mutation. This 
patient had an unusual phenotype for a BHD patient (colorectal, oesophageal and renal 
cancers) and it can be suggested that this severe phenotype might have resulted from the 
combination of germline FLCN and TP53 mutations. It also raises the possibility that 
functional genetic variants in TP53 might be tested as candidate modifiers in BHD patients. 
Though ARHGEF5 was not commonly mutated in sporadic RCC it is interesting to note that 
at least one somatic truncating mutation was detected in sporadic RCC and it would be 
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